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Chapter 1 
 General introduction 
Dissertation organization 
This dissertation consists of four chapters. The first chapter is a literature review and 
gives a brief introduction of gene therapy, different viral vectors used in gene therapy, types 
of nonsense suppressor tRNAs, their characteristics and deficiencies, various therapeutic 
options available for treatment of genetic diseases caused by nonsense mutations, their 
disadvantages compared to using suppressor tRNAs, nonsense mediated mRNA decay, and 
the research objectives of this study. 
The data in second chapter titled “U6 promoter enhanced GlnUAG suppressor tRNA 
has higher suppression efficacy and can be stably expressed in 293 cells” show that U6 
promoter can be used to increase efficacy of suppressor tRNAs. The data also show that it 
can be stably expressed in mammalian cells without any drastic adverse effects. Finally, we 
look for any proteomic changes in cells expressing GlnUAG suppressor tRNA by 2D gel 
electrophoresis. All of the research/experimental work in this chapter was performed by me, 
and this will be submitted to a peer-reviewed scientific journal for publication. 
The third chapter, titled “Design of viral vectors for Glutamine-Amber suppressor 
tRNA in vivo expression” shows the construction of a novel viral vector to express 
suppressor tRNAs in vitro and in vivo. This chapter consists mostly of in vivo data; the entire 
research mentioned here was carried out by me, and the results will be published shortly in a 
peer-reviewed journal. The experiments here demonstrate that a GlnUAG suppressor tRNA 
expressed through a viral vector can suppress a premature termination codon in SEGFP mice. 
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In addition, this work illustrates that a viral vector can be used to express a GlnUAG 
suppressor tRNA in vivo for a long period without any drastic effects. 
The fourth and final chapter summarizes the conclusions and salient features of this 
study.  
 
Gene therapy 
The central dogma of life as hypothesized by Francis Crick in 1958 describes the flow 
of information from DNA to mRNA to proteins. Any changes in any of these processes result 
in phenotypic changes and sometimes are apparent as diseases or physical deformities in 
humans. DNA changes can be the most damaging because they are irreversible and may be 
transmitted to offspring. Currently, most genetic diseases/abnormalities in humans do not 
have a cure, but gene therapy has been proposed as a technique (Osterman, Waddell et al. 
1971; Rogers 1971) to rectify mutations in DNA for treating such incurable diseases. Gene 
therapy was supposed to be the main one-step treatment for diseases that cannot be 
effectively handled by traditional medical methods (Rogers 1971). 
In theory, the process of gene therapy is simple, at least for monogenic disorders: it 
involves transfer normal copies of genes into cells that carry mutated genes. However, in 
practice, gene therapy has been a tough idea to implement. Over the years, several aspects of 
genetics and molecular biology not known before have come to light, and, in this process, the 
technical enormity of gene therapy has slowly dawned on researchers. Despite the many 
challenges, gene therapy continues to promise hope for patients suffering from incurable 
genetic disease with little or no therapeutic assistance. 
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Gene therapy can be broadly classified as somatic and germ-line gene therapy. The 
former involves the transfer of genes into somatic cells, and, hence, any modifications in the 
cells are not transmissible to the offspring. However, in the latter, as germ cells are modified, 
alterations are inherited by the offspring. Due to the inherent dangers of germ-line gene 
therapy and the ethical/moral issues involved, it is not actively pursued. 
Gene therapy has evolved into a treatment option for not only inherited monogenic 
genetic disorders such as DMD, SCID, and Cystic fibrosis, but also for acquired disorders 
like various types of cancers, cardiovascular disorders, and AIDS. Fig. 3 summarizes the 
types of diseases for which gene therapy clinical trials are underway in different parts of the 
world. The possibilities for treatment options with gene therapy may be endless, but there are 
a few major obstacles that need to be overcome before considerable strides can be made on 
this front. 
Any gene therapy protocol begins with characterization of the genetics of a given 
disease. Once the gene and the mutations that cause the disease are identified, the next step 
would be trying out various options for replacing the gene in defective cells. Various 
parameters like transcriptional regulation of the gene, its activity/efficacy, delivery to cells, 
and duration of treatment need to be optimized in cell culture. The final step before testing on 
humans would be to test the toxicity and efficacy of the treatment in an animal model system. 
Therapeutic genes can be delivered into defective cells/tissues by several methods, 
but viral vectors are best suited for this process. However, in some cases, naked DNA can 
also be delivered into cells using liposomes, electroporation, or other techniques (Fratantoni, 
Dzekunov et al. 2003; Schmidt-Wolf and Schmidt-Wolf 2003; Wolff, Lewis et al. 2005). 
Modified viruses are mostly preferred because they have high specificity and are more 
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efficient in delivering genes into the target cells (Tomanin and Scarpa 2004; Gardlik, Palffy 
et al. 2005). As shown in Fig. 4, a large number of clinical trials utilize a variety of viral 
vectors for gene therapy. The three most promising viral vectors are compared in the Table 1, 
and, from this table, it is clear that different vectors have their own advantages. Depending 
on the final objective, the type of target cell, and the gene to be delivered, viral vectors can 
be selected/modified for gene therapy. For example, if only a temporary gene expression is 
needed (as in suicidal cancer gene therapy), adenoviral vectors are the most suited for the 
job. And for steady, stable and long term gene expression, retroviral vectors are preferred. 
 
Nonsense associated diseases and therapies 
Nonsense mutations lead to premature termination of translation. Truncated proteins 
can also have varying effects on a cell. In some cases, the lack of a functional full length 
protein leads to diseases like muscular dystrophy or SCID (depending on the function of the 
protein). But, it has been hypothesized that the disease symptoms in these cases are more due 
to haploinsufficiency than due to truncated proteins. Nonsense mutations are known to cause 
several types of diseases in humans, classified as nonsense associated diseases (NADs). As 
of now, no therapeutic drugs are available to prevent or cure most of these diseases. Several 
novel approaches are under experimentation, though, and they are summarized in the Fig. 1 
(Kuzmiak and Maquat 2006). Each of these techniques has its own advantages and 
disadvantages. The most promising options, aminoglycosides and antisense therapy, are 
explored in detail here. 
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Aminoglycosides 
Aminoglycosides are a class of antibiotics that can bind to the small subunit of rRNA 
that monitors the tRNA anticodon- mRNA codon interactions during translation(Burke and 
Mogg 1985). When aminoglycosides bind to these decoding sites, they induce 
conformational changes that diminish the capability of rRNA to differentiate between tRNAs 
(Fourmy, Recht et al. 1996; Recht, Fourmy et al. 1996; Fourmy, Yoshizawa et al. 1998; 
Yoshizawa, Fourmy et al. 1998). This reduction in accuracy to discriminate tRNAs increases 
the probability of translational misreading or read through of nonsense mutations.  
Initially, aminoglycosides were used in prokaryotes. But, later on, there were several 
reports of read through of mutations causing diseases like cystic fibrosis (Howard, Frizzell et 
al. 1996; Bedwell, Kaenjak et al. 1997), Duchenne muscular dystrophy (Barton-Davis, 
Cordier et al. 1999), Hurler syndrome (Keeling, Brooks et al. 2001), infantile neuronal ceroid 
lipofuscinosis (Sleat, Sohar et al. 2001), cystinosis (Helip-Wooley, Park et al. 2002), X-
linked nephrogenic diabetes insipidus (Schulz, Sangkuhl et al. 2002), and recessive spinal 
muscular atrophy (Sossi, Giuli et al. 2001). They have also been shown to suppress nonsense 
mutations in the p53 (Keeling and Bedwell 2002) and ATM tumor suppressor genes (Lai, 
Chun et al. 2004).  
Of these, the most encouraging results have been from experiments using mouse 
model systems for DMD and cystic fibrosis (Arakawa, Shiozuka et al. 2003). Because of 
these results, clinical trials in humans with these diseases are in progress to gauge the 
therapeutic efficacy of aminoglycosides (Wilschanski, Famini et al. 2000; Politano, Nigro et 
al. 2003). 
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Several types of aminoglycosides can lead to read through of nonsense codons, and 
studies to compare the efficacy of drugs (Diop, Chauvin et al. 2007) like hygromycin, 
gentamicin, and other aminoglycosides have shown that hygromycin has the highest read 
through efficiency. 
Despite all this progress, some outstanding issues with using aminoglycosides for 
suppression of PTCs remain. Advantages of using these are that they are easy to produce, 
easy to administer, can be used for a variety of diseases, do not lead to large-scale read 
through, and new variations can be easily designed. Drawbacks of these drugs is that they are 
not codon/context dependent in read through of PTCs, are less efficient than suppressor 
tRNAs, permeability varies with cell/tissue type, may generate free radicals that cause tissue 
damage, and may lead to ototoxicity and/or nephrotoxicity with long-term use (Warady, 
Reed et al. 1993; de Jager and van Altena 2002). Of late, the other dilemma has been that 
NMD pathways eliminate all mRNAs with nonsense mutations, and this leaves 
aminoglycosides with no substrate to act upon. Thus, aminoglycosides are rendered 
ineffective in the presence of an active NMD pathway(s). Nevertheless, efforts to develop 
new types of compounds that function better without the associated side effects have been 
encouraging (Arakawa, Shiozuka et al. 2003).  
 
Antisense therapy/targeted gene repair 
Unlike aminoglycosides and suppressor tRNAs that suppress nonsense mutations at 
the translational level, the antisense gene therapy approach rectifies the mutation at the DNA 
level. Antisense therapy exploits cellular DNA repair machinery for replacing a small stretch 
DNA with mutations. Essentially, a 70 to 80 base pair oligo with self complementary 
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sequences that can fold into a double hairpin structure to escape nuclease digestion is 
transfected into cells with mutations. This oligo hybridizes with the mutant sequence except 
at the site of the mutation, where it forms a bubble. Then, DNA mismatch repair pathway(s) 
facilitate exchange of the wild type oligo in place of the mutant sequence. 
This approach has been successfully demonstrated in yeast and in mammalian cells to 
suppress mutations causing defects like sickle cell anemia (Cole-Strauss, Yoon et al. 1996) 
and thalassemia (Dominski and Kole 1993). Animal model systems of tyrosinemia (Alexeev 
and Yoon 1998), muscular dystrophy (Rando, Disatnik et al. 2000) and hemophilia (Kren, 
Bandyopadhyay et al. 1998) have been used to demonstrate a partial functional restoration of 
the defective gene. 
The biggest advantage of the antisense therapy approach is that it can be used to 
correct not only nonsense mutations, but also point mutations, small deletions, insertions, 
frameshifts, or splicing defects. However, several disadvantages exist (Parekh-Olmedo, 
Ferrara et al. 2005): (i) design and delivery of efficient oligos can be tricky; (ii) after delivery 
of oligos into cell/tissues of interest, the correction mediated by integration of the oligo into 
the DNA is dependent on the efficacy of that cell/tissue repair mechanisms; (iii) population 
of corrected cells decreases over time; (iv)and, some of the altered cells may undergo 
apoptosis. 
 
Nonsense mediated mRNA decay 
Transcription of mRNAs from DNA is a tightly regulated and highly efficient process 
with appropriate checks and balances. But, since evolution has designed this process to be 
more efficient than accurate, there are bound to be errors in mRNA. These random errors 
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(missense/nonsense mutations, insertions, or deletions) change the coding frame of the ORF 
and, more often than not, result in premature termination of translation. If the cell ends up 
with a large population of truncated proteins, depending of the function of the protein, it 
would be toxic to the cells. To counter that risk, cells have developed a quality control 
mechanism that eradicates mRNAs with premature termination codons (PTCs) in their ORFs. 
This process of elimination of nonsense mutation bearing mRNAs is known as nonsense 
mediated mRNA decay or NMD in short (Peltz, He et al. 1994; Whitfield, Sharpe et al. 
1994). NMD is a highly evolved and conserved pathway that is present in all eukaryotes and 
plants (Lew, Enomoto et al. 1998). The NMD pathway is summarized in the Fig. 2 (Maquat 
2005). Essentially, most mammalian genes with introns are susceptible to NMD pathway. 
Transcripts that have a premature stop codon anywhere except in the last exon or in the 20 to 
55 nucleotides upstream of the last exon junction complex, are degraded by the NMD 
pathway. Intronless genes or transcripts that have stop codons in the last exon region are not 
recognized by the NMD pathway and thus escape elimination. 
Although the whole process of NMD is yet to be unraveled, what’s clear is that lower 
eukaryotes like yeast have a different process of NMD compared to mammalian cells (Isken 
and Maquat 2007). Essentially, during translation, mRNAs are scanned for any premature 
stop codons, and, if any exist, these mRNAs are eliminated by the NMD pathway. Species 
differ by how a given stop codon is defined as PTC and how the NMD components are 
enlisted (Peltz, He et al. 1994; Whitfield, Sharpe et al. 1994; Gonzalez, Bhattacharya et al. 
2001; Maquat 2005).  
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NMD and NAD 
Study of the NMD pathway has importance not only for better understanding of 
cellular mechanisms but also for designing therapeutic approaches for nonsense mutation 
associated diseases (Frischmeyer and Dietz 1999; Khajavi, Inoue et al. 2006). As mentioned 
earlier, a large proportion of genetic diseases are caused due to nonsense mutations. 
Therapeutic approaches for these diseases do need to take into account that NMD will 
degrade the mutant mRNAs and, in the absence of mRNAs, translation cannot occur. Hence, 
it is imperative to understand in detail the association between NMD pathways and nonsense 
associated diseases. 
Any remedial procedures for overcoming nonsense mutations must take into 
consideration that the NMD pathway essentially eliminates all mRNAs with PTCs. This is 
one of the main reasons that aminoglycosides are not always effective (Linde, Boelz et al. 
2007). The conundrum is that as NMD pathway degrades mRNAs with nonsense mutations, 
aminoglycosides would not have any substrate to act on and, eventually, proteins are not 
produced from these genes. This presents an ideal situation to propose suppressor tRNAs as a 
viable alternative to aminoglycosides because suppressor tRNAs are known to inhibit NMD 
(Gozalbo and Hohmann 1990).If tRNAs in a cell recognize stop codons and insert an amino 
acid there, then NMD pathway would not be activated. In the case where NSTs are used for 
gene therapy of nonsense associated diseases, then NMD pathway does not require 
consideration as it is not activated (or is inhibited by the suppressor tRNAs). Table 3 
compares benefits and drawbacks of using aminoglycosides, antisense therapy, and nonsense 
suppressor tRNAs for treatment of NADs. 
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Nonsense suppressor tRNAs 
The main objective and focus of this dissertation is on how to use nonsense 
suppressor tRNAs for gene therapy. In the rest of this chapter, suppressor tRNAs are 
described in detail, including types of NSTs, their main characteristics, and factors affecting 
suppressor tRNAs. 
During translation, ribosomes “read” mRNAs three nucleotides at a time to assemble 
a growing chain of amino acids and generate peptides that are later assembled into complex 
proteins. When ribosomes are attached to mRNAs, charged tRNAs, unique to each codon, 
provide the specific amino acids. Although 20 amino acids are commonly found, there are 61 
tRNAs for each of the codons found in mRNAs. Three other codons (TAG, TGA, and TAA) 
function as stop codons for terminating translation. There are no tRNAs that can recognize 
these stop codons. 
Sometimes a normal tRNA can randomly mutate to recognize a stop codon. Such 
tRNAs that can recognize a stop codon are known as nonsense suppressor tRNAs or NSTs. 
These are a class of tRNAs that are not normally found in all cells but can recognize normal 
stop codons and insert an amino acid there (Brody S 1965; Smith JD 1966). NSTs are found 
and are functional in all organisms, from plants to animals (Chen, Ulmasov et al. 1998; Beier 
and Grimm 2001). However, their presence is hard to detect as there not many phenotypic 
tell-tale changes when suppressor tRNAs are expressed in a cell.  
 
Suppression 
Mutations are random heritable genetic changes that fuel evolution. Depending on the 
type, mutations may modify the phenotype and bestow advantages or disadvantages upon the 
11 
 
 
species. Suppression is a secondary “event” that masks the effects of these primary 
mutation(s) and restores the wild-type phenotype. Thus, if a cell harbors both a primary 
mutation and a secondary mutation that can “suppress” the former, the cell exhibits wild-type 
(normal) phenotypic features. Suppression can be phenotypic or genotypic. 
Phenotypic suppression -- These are mostly environmental effects that can alter the 
phenotypic effects of a mutation. The mutant phenotype is restored if the “environmental 
factors” are removed. For example, at low concentrations, aminoglycosides can suppress 
both nonsense and missense mutations (Martin, Mogg et al. 1989). In some cases, translation 
of mRNAs harboring such mutations can be prematurely terminated and loss of 
protein/function may be noticeable. But if these cells are treated with aminoglycosides, 
translation is not terminated because these compounds have the ability to read through PTCs. 
In these scenarios, proteins are restored, and cells may appear normal. 
Genotypic suppression -- In genotypic suppression, a secondary mutation at a different 
location in the genome can mask the effects of a primary mutation. Genetic suppression can 
last a lot longer than phenotypic suppression. For example, nonsense suppressor tRNAs can 
lead to read through of nonsense mutations. Several types of events can fall under the 
genotypic suppression class, some of which are described below: 
1. Intragenic suppression: These are compensatory mutations in the same gene. 
Sometimes, single nucleotide change can revert back it to the wild-type codon (intracodon 
suppression), or insertion/deletion of nucleotide can restore the original reading frame 
(frameshift suppression). Missense mutations in a gene can alter secondary/tertiary structure 
of the protein it codes for. In rare cases, distant compensatory mutations in the same gene can 
restore some functionality of that protein. 
12 
 
 
2. Extragenic suppressors: These are compensatory mutations in a different gene, and  
they can be codon specific. For example, nonsense suppressor tRNAs can read through 
nonsense mutations or frameshift suppressor tRNAs can read four bases unlike normal 
tRNAs that read three bases during translation.  
Apart from the types of suppressions mentioned above, several other phenomena also 
camouflage effects of a primary mutation. Protein modifications, changes in signal 
transduction pathways, or modifications in transcriptional/translational mechanisms can all 
restore wild-type phenotypic features. 
 
Types of Suppressor tRNAs 
There are two broad types of suppressor tRNAs: frameshift and nonsense suppressors. 
In frameshift mutations, a nucleotide(s) is inserted or deleted in the normal ORF of a gene, 
resulting in changes of the reading frame such that all the downstream codons are now 
coding for different amino acids during translation. More often than not, they result in 
premature termination of the ORF. Frameshift suppressor tRNAs (Tucker, Murgola et al. 
1989; Qian, Li et al. 1998) have modified anticodons, generally four bases in the anticodon 
loop, which can recognize +1 frameshift mutations. Such suppressor tRNAs can only 
function to rectify +1 frame shifts. 
Nonsense suppressor tRNAs (NSTs) recognize stop codons during translation and 
insert an amino acid they carry at that stop codon. In fact, NSTs can recognize any one of the 
three naturally found stop codons and can incorporate a specific amino acid. NSTs are found 
in prokaryotes and eukaryotes, including plants and mammals. 
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NSTs were first discovered in 1971 in E.coli infected with RNA phage Qβ (Sakano, 
Yamada et al. 1974). These phages can make a full-length coat protein only in the presence 
of a UGA suppressor tRNA(Sakano, Yamada et al. 1974). Eukaryotic and plant NST were 
later identified in MLV infected animal tissues and TMV infected plant tissues respectively 
(Pelham 1978; Yoshinaka, Katoh et al. 1985). Since then, NSTs have been characterized in 
yeast, Drosophila, C.elegans, and other eukaryotes (Laski, Ganguly et al. 1989; Pilgrim and 
Bell 1993; Li, Linning et al. 1998; Srinivasan and Gopinathan 2001).  
 
Types of NSTs in eukaryotes: 
NST nomenclature uses the stop codon as a prefix for the tRNA and the amino acid 
inserted as a superscript. For example, UAG tRNATyr or Amber tRNATyr stands for a NST 
that recognizes a UAG stop codon and inserts a tyrosine amino acid there. Such 
nomenclature also indicates that a cellular tRNA that recognizes tyrosine anticodons and is 
charged with tyrosine can have a mutation in the anticodon, and, because of which, it now 
recognizes UAG. NSTs are grouped according to the stop codons they recognize as follows:  
UAG suppressor tRNA 
This was the first NST identified from Drosophila (Laski, Ganguly et al. 1989) on the 
basis of its ability to read through a premature UAG codon. It has an unusual anticodon, 
GψA, and is charged with a tyrosine. Plants have a similar NST. Apart from these, other 
NSTs have been identified that are charged with glutamine and leucine. All of these have 
modified anticodons, the importance of which is discussed later. 
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UAA suppressor tRNA 
This is the weakest NST in the sense that stop codon recognition is least efficient, so 
viruses that depend on NSTs do not prefer this codon (UAA) for read through during 
translation. Most of the UAG suppressors act as isoacceptors and recognize the UAA codon. 
A few exclusive UAA suppressors might exist. 
UGA suppressor tRNA 
UGA is the optimal codon for viruses as it’s a very “strong codon” in the sense that it 
is recognized much more efficiently by the NSTs. Naturally occurring opal NSTs carry 
tryphtophan, cysteine and arginine. Furthermore, UGA tRNATrp is used in rabbit 
reticulocytes to make full-length β-globin protein (Hatfield, Thorgeirsson et al. 1988; 
Chittum, Lane et al. 1998).  
 
Features of Nonsense suppressor tRNAs: 
Although there have been sporadic reports of naturally occurring suppressor tRNAs 
in all organisms, including eukaryotes like yeast and humans, it is generally accepted that 
NSTs are not a universally occurring evolutionarily conserved phenomenon. In all 
probability, NSTs are chance secondary mutations in a normal tRNA(s) that suppress a 
corresponding primary point mutation in another cellular gene. All NSTs, however, share 
some common features that are summarized below: 
• They are derived from naturally occurring cellular tRNAs and, hence, have 
similar structure and functional capabilities like normal tRNAs. 
• They are transcribed and processed as normal cellular tRNAs. 
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• They are charged by the same amino acyl synthetase that charges the normal 
tRNA from which they are derived. 
• They recognize any one of the three stop codons and insert a specific amino 
acid there. 
• NSTs are not charged as efficiently as the cognate tRNAs, and they do not 
recognize the cognate stop codons as efficiently too.  
• But, depending on the nucleotides surrounding the stop codons, they can 
recognize the mutant stop codons quite efficiently. 
 
Factors affecting efficacy of nonsense suppressor tRNAs 
tRNA transcription and processing is a highly regulated and streamlined process. 
Amino acyl synthetases not only play a major role in translation as they charge the tRNAs 
with the right amino acid, they also have several other cellular functions (Kyriacou and 
Deutscher 2008). In addition, mutations in amino acyl synthetases are known to cause 
genetic diseases in humans (Antonellis and Green 2008). Suppressor tRNA activity is 
connected to amino acyl synthetase activity and other factors. These factors are discussed as 
below.  
1. NST transcription: differential expression 
tRNA genes are transcribed by RNA Polymerase III enzyme that in turn depends on 
Pol III promoters for transcribing these genes. Even though tRNA genes are small, they do 
have internal Pol III promoters, and, unlike Pol II transcribed genes, tRNA genes do not need 
an external promoter or enhancer for transcription. As NSTs are derived from naturally 
occurring cellular tRNAs, they inherit all their features mentioned above. It is known that 
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tRNA genes are differentially transcribed and suppressor tRNAs follow similar patterns (Li, 
Linning et al. 1998; Srinivasan and Gopinathan 2001). In fact, they are processed by the 
same cellular machinery that deals with normal tRNAs. Hence, suppressor tRNAs are 
differentially expressed depending upon the type of cell/tissue. This is a crucial factor that 
requires attention when gene therapy protocols involving suppressor tRNAs are designed. 
2. NST charging 
Amino acids are enzymatically added to tRNAs by aminoacyl tRNA synthetases 
(aaRSs) (Chambers 1971; Jacobson 1971). There are 61 tRNAs in eukaryotic cells, while 
there are only 20 aaRSs to recognize and charge all these tRNAs. Charging of tRNAs by 
aaRS is a tightly regulated, highly conserved, and efficient process. Synthetases differentiate 
tRNAs basing on a set of unique “identity elements” (Gieg‚ Sissler et al. 1998). These 
elements can be a single nucleotide in the anticodon loop of the tRNA or a stretch of 
nucleotides in one arm of the tRNA. Depending on the tRNA from which they were derived, 
NST charging efficiency by synthetases varies. Sometimes, if the identity element is the 
nucleotide in the anticodon loop, and that has been modified to convert it to a suppressor 
tRNA, then the charging efficacy is very low. Or, if the identity elements are not present in 
the anticodon loop, the charging efficacy might be slightly better. In any scenario, tRNA 
bases are highly conserved and every single nucleotide in the tRNA sequence contributes to 
the final tertiary structure. Hence, any changes in the tRNA bases would affect its charging 
by varying degrees. 
A very remote possibility exists that NSTs may have their unique aaRS for charging, 
but as of now, we have no evidence/rationale to substantiate such hypothesis. Suppressor 
tRNAs do use normal cellular aaRS for charging. And when NSTs use regular cellular 
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aaRSs, the charging efficiency is not that high. As a result, the suppression efficacy (i.e. the 
efficacy at which a give NST recognizes a mutant stop codon and inserts an amino acid 
there) goes down. 
3. The fourth base and release factors 
After a NST is transcribed, processed, and charged, it has to recognize a mutant stop 
codon during translation to insert an amino acid there. Traditionally, the stop codon is known 
to be made up of only three bases. However, that a fourth base involved is increasingly 
evident (Cassan and Rousset 2001). The fourth base is the base immediately after the three 
bases that make up the stop codon. Of the four nucleotides found on mRNAs, Uracil as the 
fourth base is very effective for increasing the strength of a translation termination signal, 
while adenosine is least effective. And it is logical that most naturally occurring stop codons 
have Uracil as the fourth base. In addition, there are reports that other nucleotides around the 
stop codon are not random. 
Eukaryotic translation termination is largely mediated by two molecules known as 
eukaryotic release factor 1 (eRF1) and eukaryotic release factor 3 (eRF3). During translation, 
when ribosomes reach a stop codon, the release factors terminate translation and release the 
nascent peptide chain. But when a normal codon mutates to a nonsense codon, more often 
than not, its surrounding nucleotides are not what are generally found around natural stop 
codons. Depending on where the mutation has occurred, nonsense mutations can be very 
strong or weak. NST read through efficacy depends a great deal on this. If the fourth base of 
a PTC is conserved, the NST efficacy would be low, and if it is not a conserved base, then 
the read through efficacy would be high. 
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When both NSTs and release factors are present in the same cell, they are in 
competition to bind to the stop codons (natural and nonsense mutation). If the stop codon is 
strong, then release factors bind and terminate translation (if it is a PTC, then we would see a 
truncated protein). On the other hand, if the stop codons are weak, then NSTs bind to the stop 
codons and lead to read through of translation to get a full-length functional protein.  
Generally, release factors are abundant in a cell, and NSTs are out competed because 
they cannot recognize the stop codons efficiently. It has been shown that when one of the 
release factors is depleted from the cell, the suppression efficiency of NSTs increases. 
Naturally occurring stop codons are followed by a specific nucleotide that increases its 
affinity toward release factors that terminate translation (Drugeon, Jean-Jean et al. 1997; 
Cassan and Rousset 2001; Ilegems, Pick et al. 2004; Janzen and Geballe 2004).  
4. Suppressor tRNA toxicity 
Theoretically, if suppressor tRNAs can recognize mutant stop codons and insert an 
amino acid there, they should also be capable of binding to normal stop codons and inserting 
an amino acid there. That would lead to elongation of normal peptides, resulting in abnormal 
and potentially harmful/toxic proteins. Some researchers believe this to be the reason for cell 
death that has been observed in some models when suppressor tRNAs are stably and 
constitutively expressed in cells (Hudziak, Laski et al. 1982; Laski, Ganguly et al. 1989). But 
as mentioned above, the strength of naturally occurring stop codons and their competition 
with release factors for strong stop codons decreases the chances of suppressor tRNA related 
toxicity. Also, there are reports that cells may have evolved to have natural stop codons 
followed by multiple stop codons to prevent accidental read through, which may result in 
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abnormal proteins (Bienz, Kubli et al. 1981). However, this theory needs to be examined in 
more detail to substantiate these claims. 
 
Potential applications for suppressor tRNAs 
Suppressor tRNAs have been found in a variety of organisms for different functions 
(Kuchino and Muramatsu 1996). More often, they arise as a secondary mutation that is 
retained to suppress a primary mutation in a different gene. The secondary event acts as a 
gain of function mutation bestowing evolutionary/survival advantages. 
Researchers have proposed several unique applications using suppressor tRNAs, 
some of which are described below: 
1. Suppressor tRNAs can be used as gene therapy tools to read through 
transcripts with premature stop codons(Temple, Dozy et al. 1982). Full-length 
functional proteins can be made by using suppressor tRNAs in translation.  
2. Toxin genes, like diphtheria genes, with nonsense mutations can be 
transferred into cancer cells, and suppressor tRNA genes can be used to regulate the 
gene expression (Robinson and Maxwell 1995). NSTs might be useful in such cancer 
therapy protocols. In addition, suppressor tRNAs can be used to regulate expression 
of any toxic genes in cells/tissues. 
3. A similar technique was used to study aspects of visual system 
development in Drosophila melanogaster. Suppressor tRNAs can be used to 
selectively express toxin genes in cells at different stages of development and analyze 
the results (Kunes and Steller 1991). 
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4. Another major area for suppressor tRNA usage is in unnatural amino 
acids (Xie and Schultz 2005; Liu, Brock et al. 2007). Unnatural amino acids have a 
whole spectrum of applications ranging from analytical studies in cellular 
development to biomarkers to studying protein interactions to protein functions 
(Noren, Anthony-Cahill et al. 1989; Liu and Schultz 1999; Klarmann, Eisenhauer et 
al. 2004). Suppressor tRNAs have successfully been used to insert unique unnatural 
amino acids into proteins.  
 
Choice of suppressor tRNA 
Theoretically, any normal codon in an ORF can mutate to a premature stop codon. 
But surprisingly, from the data amassed over the years and from all the nonsense mutations 
in humans cataloged in the Human Mutation Database, we know that some amino 
acids/codons are not known to mutate into nonsense codons. These include Ala, Asn, Asp, 
His, Ile, Met, Phe, Pro, Thr, and Val. And there are some amino acids/codons, like Arginine, 
for which the only known nonsense codon mutation is an Opal (UGA). Table 2 summarizes 
the complete data of amino acids and their known corresponding PTC mutations. The reasons 
for these peculiar features are not yet clear. 
After analysis of these data, we chose to use GlnUAG suppressor tRNA for our 
research in this dissertation. The main reason for this is that UAG nonsense mutations are the 
most frequently occurring stop codon mutations. Of these, Glutamine to Amber/Ochre stop 
codon mutations are the highest number of nonsense mutations. In addition, the animal 
model system we selected, SEGFP transgenic mice, has PTC in the GFP gene where a UAG 
stop codon inserted at the third codon position in the GFP ORF prevents GFP protein 
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expression (Ro and Rannala 2004). We, therefore, decided to use GlnUAG suppressor tRNA 
for our research.  
 
Research Objectives 
The main focus of this dissertation is to try and devise methods for using suppressor 
tRNA in gene therapy of diseases caused due to nonsense mutations. Researchers proposed 
use of nonsense suppressor tRNAs in gene therapy over two decades ago (Temple, Dozy et 
al. 1982). But due to various reasons elaborated earlier, no real progress has been made in 
that direction. We have identified crucial bottlenecks in the technique of using suppressor 
tRNA and attempted to make some improvements. The key research objectives of this thesis 
are the following:  
1. Increase suppression tRNA expression and efficacy. 
For suppressor tRNA mediated therapy to be successful, NSTs have to be very 
effective to read through premature stop codons. Suppressor tRNAs are similar to cognate 
tRNAs, but they are not as efficiently charged by amino acyl synthetases and have to 
compete with translation termination factors. We hypothesized that if more suppressor tRNA 
is made in cells, they would compete better with cognate tRNAs for charging and, hence, can 
be more effectively charged. More number of charged suppressor tRNAs can compete better 
with release factors. All of this would result in better read through of premature stop codons. 
Therefore, the first step would be to devise methods to increase suppressor tRNA expression 
and efficacy. 
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2. Design methods to efficiently express suppressor tRNA in various cell types at 
functionally relevant levels. 
Nonsense mutations can occur in any gene, any cell type. The methods that increase 
suppressor tRNA expression should be appropriate enough to work in different cell types or 
tissues. As mentioned earlier, even if suppressor tRNAs are expressed in a cell, their main 
function (read through of PTCs) is complete only when the normal phenotypic function is 
restored. In other words, enough suppressor tRNA should be expressed to make full-length 
normal protein. Hence, our second objective is to come up with techniques that express 
suppressor tRNA in all types of cells at functionally relevant levels.  
3. Study effects of long-term and stable expression of suppressor tRNAs. 
The main argument against using suppressor tRNAs for gene therapy has been that if 
stably expressed, they are toxic to cells. The hypothesized reason was that suppressor tRNAs 
read through normal stop codons and result in abnormally elongated lethal proteins. This 
hypothesis has never been examined thoroughly. We have devised studies to stably express 
suppressor tRNAs in mammalian cells and examine the resulting changes in whole cell 
proteins. This would go a long way in clearing any apprehensions about the toxicity of 
suppressor tRNAs.  
4. Design efficient viral vector for in vivo expression of suppressor tRNAs. 
Gene therapy protocols require targeted gene delivery into cells carrying defective 
genes. Gene expression where it is not required can be counter productive and may have 
deleterious effects. Targeted gene delivery is best achieved with viral vectors; these are also 
the most effective for gene delivery in animals. To date, only adenoviral vectors are known 
to transfer suppressor tRNAs at a functionally relevant levels. But, adenoviral vectors cannot 
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express genes for a long term, and they have other issues too. In this dissertation, we attempt 
to design a novel and efficient viral vector for expression of suppressor tRNAs in different 
cell types. We also try to show that suppressor tRNAs expressed through these vectors can 
effectively suppress a premature stop codon to make full-length proteins. 
5. Use suppressor tRNA for gene therapy in an animal model system. 
The last and most vital objective is to use the novel vector with all the improvements 
in an animal model system. SEGFP mice, transgenic mice expressing mutant GFP, are used 
as model system. The objective is to use the novel viral vector to express suppressor tRNA in 
mice and show that the suppressor tRNA can suppress PTC in the SEGFP gene, resulting in 
expression of full-length GFP. 
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Figure 1: Summary of therapeutic options available for treatment of genetic diseases 
caused due to nonsense mutations. {Kuzmiak, H.A. and L.E. Maquat;. Trends in molecular medicine, 
2006. 12(7): p. 306-16}.Potential therapies for nonsense associated diseases are illustrated here. 
(a) Binding of aminoglycosides to the ribosome decreases its proof reading capability and, 
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thus, enables binding of near cognate tRNAs to the stop codon and read though of mRNAs 
with PTCs. (b) Modified antisense DNA oligonucleotides (AOs) can be used to repair a 
disease associated mutation. AO-mediated DNA repair can also be used to alter DNA 
sequences that change other aspects of gene expression, including pre-mRNA splicing. (c) 
Plasmids carrying a suppressor tRNA gene can be introduced into human cells. The encoded 
suppressor tRNA contains an anticodon that is complementary to the disease-associated 
nonsense codon. Because the tRNA becomes aminoacylated once it is synthesized in human 
cells, it directs amino acid incorporation at the nonsense codon. (d) AOs that are 
complementary to pre-mRNA-specific sequences that regulate splicing can be used to alter 
splice-site choice. By doing so, the structure of spliced mRNA can be therapeutically 
manipulated (e.g. it might be possible to skip one or more exons that harbor a disease-
associated nonsense or frameshift mutation and restore the site of translation termination to 
normal). Although the encoded protein contains a deletion, the deletion might interfere less 
with protein function than the truncation caused by the nonsense or frameshift mutation. (e) 
Upregulating or otherwise inducing expression of a protein that can functionally substitute 
for the disease-associated protein might provide a useful therapy for diseases in which an 
alternative protein of comparable function exists. (f) In theory, AOs might also be used to 
block NMD of a disease-associated mRNA by specifically blocking the interaction between 
the UPF1 NMD factor, which is a constituent of the SURF complex, and the UPF2 NMD 
factor, which comprises the EJC. Having escaped NMD, the disease associated transcript 
could then be targeted for nonsense suppression as described above to generate more full-
length protein than would be possible without the mRNA specific inhibition of NMD. 
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Figure 2:  Summary of nonsense mediated mRNA decay in mammalian cells. 
NMD occurs in every type of cell or tissue analyzed to date, but the mechanism of 
NMD varies in higher and lower eukaryotes. NMD in mammals is summarized here. In 
mammalian mRNAs, if a stop codon happens to be positioned upstream of 50 to 55 
nucleotides of the last exon junction complex, then such a stop codon is considered a 
premature termination codon. These mRNAs are then eliminated by NMD. If the stop codon 
mutation occurs in the last exon, the mRNAs are not subjected to NMD.  
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  Ref: J Gene Med 2007; 9: 833–842. 
Figure 3: Diseases addressed in gene therapy clinical trials. 
Various types of diseases addressed by gene therapy to date are compared here. A 
vast majority of these trials have targeted cancer and cardiovascular diseases because of their 
prevalence and impact on human health. Surprisingly, since 2004, more trials have been 
designed targeting cardiovascular disorders than monogenic disorders. This is despite the fact 
that trials for monogenic disorders have been more successful. The data also shows that a 
number of other diseases/disorders are under trail for therapeutic benefit by gene therapy. 
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 Ref: J Gene Med 2007; 9: 833–842. 
Figure 4: Vectors used gene therapy clinical trials. 
A number of different viral vectors have been tested for their efficacy in gene transfer 
into target cells. Despite being the most attractive on paper, retroviral vectors are being 
shunned by investigators for their propensity to cause insertional mutagenesis. Adenoviral 
vectors are the most commonly used viral vectors today, but Adeno-associated viral vectors 
are fast developing into the most attractive viral vectors for future clinical trials. Many labs 
around the world are designing gene therapy protocols with AAV vectors, and these vectors 
will reach the clinical trials stage sooner than later. Apart from these, a number of other 
viruses like vaccinia virus, poxvirus, and HSV, have been used in clinical trials for gene 
therapy.  
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Ref: Hum Mutat (2003) 21:577-581. 
Figure 5: Data of all known human mutations. 
The human gene mutation database was designed to collect information about all 
known inherited mutations that have a pathological effect in humans. Data from this database 
is shown in the figure here. From the graph, it is evident that most disease causing mutations 
in humans are missense or nonsense mutations (~50%). All the other types of mutations, 
including deletions, insertions, and complex rearrangements, comprise the other 50% of 
known mutations. The probability of occurrence of missense or nonsense mutations is very 
high compared to any other type of mutation, and the data reflects this rationale. 
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Feature Adenoviral vector AAV Retroviral vector 
Particle size (nm) 70-100 20-25 100 
Cloning capacity (kb) 8-10 ~5.0kb 8-9 
Chromosomal 
integration 
No No Yes 
Vector yield (TU/ml) High (>1012) High (>1012) Moderate (1010) 
Cellular entry CAR mediated 
endocytosis 
Receptor mediated 
endocytosis 
Receptor binding 
Transgene expression Weeks to months Long term Long term 
Oncolytic potential Yes No No 
RCR in vivo Not a major concern Not a major concern Risk is a concern 
Quiescent cell 
infection 
Yes Yes No 
Insertional 
mutagenesis 
No No Yes 
Risk of oncogene 
activation 
No No Yes 
 
 
Table 1: Features of key viral vectors. 
Several different types of viral vectors are used for gene transfer into animal cells. 
The three most prominent of these are compared in the table above.  
 
 
 
 
 
36 
 
 
Amino acid TAG TGA TAA Total 
 Ala 0 0 0 0 
Arg 0 1982  1982 
Asn 0 0 0 0 
Asp 0 0 0 0 
Cys 0 349  349 
Gln 1728 0 578 2306 
Glu 541 0 516 1057 
Gly 0 169 0 169 
His 0 0 0 0 
Ile 0 0 0 0 
Leu 77 103 77 257 
Lys 193 0 172 365 
Met 0 0 0 0 
Phe 0 0 0 0 
Pro 0 0 0 0 
Ser 125 282 156 563 
Sec 0 0 0 0 
Thr 0 0 0 0 
Trp 598 618 0 1216 
Tyr 465 0 485 950 
Val 0 0 0 0 
 
Table 2: Compilation of all amino acids and their corresponding known nonsense 
mutations in humans. (Ref: Hum Mutat (2003) 21:577-581) 
. This table is a compilation of all the amino acids and the number of pathogenic stop 
codon mutations known in humans. The data in this table can be used when therapies for 
nonsense associated diseases are designed.  
 
37 
 
 
Type of therapy Method Advantages Disadvantages Comments 
Aminoglycosides Class of 
antibiotics that 
allow read 
through using 
near cognate 
tRNAs during 
translation. 
Easy to design 
and administer, 
do not lead to 
large scale read 
through, and 
presently in 
clinical trials. 
 
 
Codon and 
context 
dependent, 
permeability 
varies with cell 
type, generate 
free radicals that 
damage tissues & 
nephrotoxicity or 
ototoxicity; 
ineffective if 
NMD pathway is 
active.  
 
Less efficient 
than suppressor 
tRNAs. 
Methods have 
to be developed 
to overcome 
NMD pathway. 
Nonsense 
suppressor 
tRNAs 
Single nucleotide 
changes in 
cognate tRNAs 
can lead to 
incorporation of 
amino acids at 
stop codons. 
Highest 
efficacy of read 
through all the 
options, highly 
specific to each 
codon, easy to 
design and 
transfect. Also, 
NMD pathway 
is inhibited by 
suppressor 
tRNAs. 
No method to 
control 
expression may 
be toxic in long 
expression, 
delivery into 
animals with a 
viral vector not 
yet optimized.  
More animal 
experiments 
required to 
study effects in 
vivo in detail. 
 
Antisense 
therapy 
Nucleotide 
exchange at 
DNA level 
Potential to 
rectify point 
mutations, 
Design and 
delivery of 
efficient oligos is 
If developed in 
future, may 
have enormous 
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replaces mutant 
bases with wild 
type sequence. 
 
small deletions, 
insertions or 
splicing defects. 
a major obstacle, 
percentage of 
corrected cells 
decreases with 
time, and 
sometimes may 
lead to apoptosis. 
 
applications. 
NMD pathway 
does not come 
into picture in 
this case. 
 
Table 3: Summary of therapies for nonsense associated diseases. 
Three of the most promising types of therapies for nonsense associated diseases are 
compared in this table. 
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Chapter 2 
U6 promoter enhanced GlnUAG suppressor tRNA has higher suppression 
efficacy and can be stably expressed in 293 cells. 
Koukuntla R1, Ramsey WJ2, Young WB2, Kisselev S2 and Link CJ Jr.1, 2 
1 – Genetics, Cellular and Developmental Biology, Iowa State University, Ames, Iowa. 
2 – NewLink Genetics Corp., Ames, Iowa 
 
Abbreviations: 
NST – Nonsense Suppressor tRNA. 
GlnUAG – Glutamine UAG (amber) suppressor tRNA. 
PTC – Premature Termination Codon. 
SEGFP – Stop Enhanced Green Fluorescent Protein. 
Abstract  
Nearly one third of all human genetic diseases are caused due to nonsense mutations that can 
result in truncated proteins. Nonsense suppressor tRNAs (NSTs) were proposed as valuable 
tools for gene therapy of genetic diseases caused by premature termination codons (PTCs). 
Although various strategies were adapted over the years to increase NST expression and 
efficacy,  low suppression efficacies of NSTs and toxicity associated with stable expression 
of suppressor tRNAs have hampered development of NST mediated gene therapy. We have 
employed the U6 promoter to enhance Gln-Amber suppressor tRNA resulting in more 
effective suppression of PTCs than the use of multimers of the same suppressor tRNA 
without a U6 promoter. Since most tRNAs have cell specific differential expression, this 
technique will enable expression of different kinds of suppressor tRNAs in various cell types 
at high, functionally relevant levels. Finally, in an attempt to study toxic effects of NSTs, 
stable cell lines that constitutively express U6 promoter enhanced GlnUAG suppressor 
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tRNAs were established. Proteomic analysis of these cells indicates that NSTs did not lead to 
significant read through of normal cellular proteins. The techniques developed here may 
contribute to the further development of suppressor tRNA mediated gene therapy. 
Introduction 
The central dogma of life describes a flow of information from DNA to mRNA to 
proteins (Strasser 2006). During translation, information in mRNAs is decoded into proteins 
by ribosomes. Translation is terminated when ribosomes reach any of the three naturally 
occurring stop codons(Cavener and Ray 1991). However, nonsense mutations in the coding 
region of the transcripts can lead to premature termination of translation (Atkinson and 
Martin 1994). Such nonsense mutations or premature termination codons (PTCs) can be 
suppressed by a class of mutant tRNAs, nonsense suppressor tRNAs (NSTs), that can 
recognize stop codons and insert an amino acid  in that site during translation (Capecchi, 
Hughes et al. 1975; Capecchi, Haar et al. 1977). 
Given that stop codons do not code for any amino acids, and that humans do not have 
cognate tRNAs that recognize stop codons, suppressor tRNA mediated gene therapy was 
postulated as an exciting prospective treatment option for diseases caused by premature 
termination of mutant transcripts (Temple, Dozy et al. 1982; Panchal, Wang et al. 1999). 
Considering that nearly one third of all genetic diseases in humans are a result of nonsense 
mutations (Atkinson and Martin 1994), NST mediated gene therapy is worth further 
investigation. Although NSTs were proposed as gene therapy tools to suppress nonsense 
mutations in vitro and in vivo, issues related to expression and toxicity of suppressor tRNAs 
have impeded any substantial progress. Nevertheless, as of now, one of the few possible 
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cures for such PTC-induced genetic diseases is suppressor tRNA mediated gene therapy 
(Kuzmiak and Maquat 2006). 
The suppression efficacy of NSTs depends on several factors, such as the strength of 
the stop codons (McCaughan, Brown et al. 1995), their affinity to the corresponding 
aminoacyl synthetase that charge tRNAs with amino acids (Gieg‚, Sissler et al. 1998), and 
copy number of suppressor tRNA genes in the cell (Buvoli, Buvoli et al. 2000). In addition, 
NSTs even have to compete with translation termination factors to bind to the stop codons 
(Ganoza and Tomkins 1970; Janzen and Geballe 2004). Although all tRNAs have their own 
strong internal RNA Polymerase III promoters, they are differentially expressed (Li, Linning 
et al. 1998; Srinivasan and Gopinathan 2001) and since NSTs are derived from cognate 
tRNAs, they are subjected to similar regulations and processing. All of the aforementioned 
factors are involved in increasing or decreasing the suppression efficacy of NSTs. It has also 
been reported that stable and long-term expression of NSTs can have detrimental effects on 
cells (Hudziak, Laski et al. 1982; Laski, Ganguly et al. 1989). 
To overcome low expression patterns of suppressor tRNAs and to design effective 
NSTs, a variety of techniques were developed by various researchers. One such strategy of 
expressing an orthogonal pair of a suppressor tRNA and the corresponding aminoacyl 
synthetase from E.coli in mammalian cells improves the charging efficacy of suppressor 
tRNA by the synthetase, but does not significantly increase the suppression efficacy 
(Drabkin, Park et al. 1996; K”hrer, Sullivan et al. 2004). Other strategies include use of 
multimers of NSTs to increase the suppression (Buvoli, Buvoli et al. 2000). Buvoli et al. had 
showed that multimers of suppressor tRNA genes increase suppression by providing larger 
amounts of substrates for the synthetases to charge and the charged suppressor tRNAs 
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compete better with release factors during translation. Most of the above strategies do not 
address the differential expression of suppressor tRNAs. In addition, the level of suppression 
achieved with these strategies might not be sufficient for gene therapy of a disease phenotype 
caused by nonsense mutations. 
In developing our model of NST mediated gene therapy, GlnUAG suppressor tRNA 
was chosen as glutamine is one of the most commonly mutated amino acids in nonsense 
mutations found in human genes. Of 9045 nonsense mutations cataloged in the Human Gene 
Mutation Database, 1697 are Glutamine-Amber stop codon mutations 
(http://www.hgmd.cf.ac.uk/ac/index.php).   
To demonstrate that suppressor tRNA mediated gene therapy is feasible, we 
addressed a fundamental limitation of current models, e.g., low transgene expression. 
Increase in suppressor tRNA expression is an effectual prerequisite for increase in 
suppression efficacy. Lai et al. have used a human U6 promoter to increase expression of a 
normal intron bearing tyrosine tRNA (Lai, Weng et al. 2004). A similar strategy was 
employed in the current study to show that a human U6 promoter enhanced Gln-amber 
suppressor tRNA has significantly higher suppression efficacy. We further employed the 
technique to suppress a PTC in the GFP gene of primary cells derived from a transgenic 
SEGFP mouse (Ro and Rannala 2004). Finally, the effects of constitutive expression of U6 
promoter enhanced Gln-amber suppressor tRNAs in 293 cells were studied.  
Materials and Methods: 
Vector construction 
 GlnUAG tRNA was designed by substituting a single base, ‘A’ in place of ‘G’ in 
the anticodon loop of the naturally occurring Gln-tRNA (Roy, Cooke et al. 1982). 
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Complementary 72bp oligos (IDTDNA, Coralville, IA) designed to have BamHI and BglII 
sites on either ends were annealed and cloned into pGEM-T EASY vector (Promega, 
Madison, WI). Then, copies of the cloned of tRNA gene were isolated following plasmid 
digestion with BamHI/BglII restriction enzymes and cloned in 5’ to 3’ orientation, as was 
done by Buvoli et al. (Buvoli, Buvoli et al. 2000). The human U6 promoter was obtained 
from pSilencer 2.0 vector (Ambion, Austin, TX) and cloned upstream of the GlnUAG tRNA. 
Multimers of these U6GlnUAG tRNA copies were then cloned into the same vector using 
MluI and NsiI sites.  
 A ‘TAG’ amber mutation was introduced into pEGFP gene (Clontech, Mountain 
View, CA) between the third and fourth codon by PCR mutagenesis using the primers – 
STOPEGFP5: 5’AAGAATTCGCCACCATGGTGGAGGAGTAGAGCAAGGGCG 
AGGAGCTGTTC3’ and 3EGFP: 5’-GTGAATTCTTACTTGTACAGCTC-3’. For 
construction of pLSEGAIN, SEGFP (stop-EGFP) gene was cloned into a lentiviral vector, 
pLEIN (kind gift of Dr.Won-Bin Young, NewLink Genetics, Ames, IA) that carries a SV40 
promoter driven neomycin as a selection marker. For DNA Mini-preps, SV Minipreps 
(Promega) was used, and for Maxi preps, GenElute HP Endotoxin-Free kit (Sigma, St.Louis, 
MO) was used. 
Cell Culture and Transfections 
Cells were cultured in DMEM (Invitrogen, Carlsbad, CA) with 10% FBS 
(Invitrogen), 2mM L-Glutamine (Invitrogen), and 5% CO2 at 37oC. Transfections were 
performed in 12 well plates with 2.5 µg of DNA per well and Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. While different plasmid vectors 
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were compared, equimolar DNA ratios were maintained for transfections. All transfections 
were carried out multiple times (in quadruplicates each time) to confirm the results. Primary 
cells were transfected after the cells were plated on a cover slip in a six well dish. The next 
day, serum free media was added to cells prior to transfection. For each well, 2.0 µg of DNA 
was diluted in 100 µl of 150 mM NaCl. 9.0 µl of 10 mM PEI (Polyethylenimine) (Sigma) 
dissolved in 100 µl of 150 mM NaCl and used for transfection of each well. DNA and PEI 
were mixed, incubated at room temperature for 10 min, and added to the cells. This was 
replaced with fresh media after 6 hr. 
Primary Cell Culture 
The brains of two day old mice were used for isolation and culturing of primary 
astrocytes. Each mouse brain was dissected, washed with cold PBS and resuspended in 
DMEM (Invitrogen) with 10% FBS, 2 mM L-Glutamine, and Pen-Strep and then incubated 
in 5% CO2 at 37oC. After 24 hr, the supernatant was discarded and astrocytes sticking to the 
flask were transferred to a fresh flask. These cells were cultured further and used for 
transfections. 
Lentiviral vector production 
Lentiviral vector carrying the SEGFP gene and a SV promoter driven Neomycin 
marker was produced by a triple transfection method in 293T cells. Three plasmids 
(pLSEGAIN, pCMV8.2, and pVSV-G) were transfected into 293T cells (ATCC, Manassas, 
VA) by calcium phosphate method (Invitrogen). Supernatant was collected after 3 days, 
filtered with a 0.45 µM filter, and used to infect 293 cells. The cells were selected with 750 
µg/mL G418 (Invitrogen) for 2 weeks to obtain stable 293 cells expressing mutant GFP 
mRNA (293/LSEGAIN). 
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Stable cell lines expressing suppressor tRNA 
To generate stable cell lines expressing GlnUAG suppressor tRNA, 293/LSEGAIN 
cells in two 500 cm2 flasks (Nunc, Rohcester, NY) were transfected with linearized pGEM-
U6GlnUAG-8 plasmid DNA using Lipofectamine. After 48 hr, GFP positive cells were 
sorted by FACS and further cultured in T185 flasks. After two more rounds of sorting for 
GFP positive cells by FACS, stable cells expressing suppressor tRNA were obtained. 
FACS and microscopy 
Cells were trypsinized, washed once with PBS and analyzed or sorted on a BD 
FACSVantage SE flow cytometry system and BD FACSDiVa option (when necessary to 
evaluate cells for toxicity, cells were incubated with 7AAD on ice for 5 min prior to sorting).  
Cells were imaged by a Zeiss Axioplan II compound microscope equipped with a AxioCam 
digital camera.  
Western Blotting 
Whole cell proteins were extracted with CelLytic M (Sigma, C2978) lysis solution. 
Cell lysate was then collected with a cell scraper and centrifuged at 12000g for 10 min at 
4oC. Supernatant containing proteins was collected and quantified using a BCA kit (Pierce).  
Protein samples were also visually quantified by silver staining (Pierce, Rockford, IL). Next, 
equal amounts of various protein samples were loaded onto a 4-12% Bis-Tris pre-cast gel 
(Invitrogen) and run at 200 Volts for 45 min. The proteins were transferred to a PVDF 
membrane (Invitrogen) and probed with 1:1000 dilutions of primary antibody (JL-8, 
Clontech for GFP and SC-24, Santa Cruz for Hsp70) for 1 hr. 1:40,000 diluted rabbit anti-
mouse HRP conjugate (Clontech) was used as the secondary antibody. The blot was 
developed with a West femto kit (Pierce) and captured onto a Kodak Biomax light film. 
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2D gel electrophoresis 
Two-dimensional electrophoresis was performed using the carrier ampholine method 
of isoelectric focusing(O'Farrell 1975) by Kendrick Labs, Inc (Madison, WI).  Isoelectric 
focusing was carried out in glass tubes of an inner diameter of 3.5 mm using 2% pH 3.5-10 
ampholines (GE Healthcare, Piscataway, NJ) for 20,000 volt-hrs. After equilibrium in the 
SDS sample buffer (10% glycerol, 50 mM dithiothreitol, 2.3% SDS, and 0.0625 M tris, pH 
6.8), each tube of gel was sealed to the top of a stacking gel that overlays a 10% acrylamide 
slab gel (1 mm thick). SDS slab gel electrophoresis was then carried out for about 5 hr at 25 
mA/gel. Duplicate gels were obtained from each sample and were scanned with a laser 
densitometer (Model PDSI, Molecular Dynamics Inc, Sunnyvale, CA). The images were 
analyzed manually and using Progenesis Discovery PG240 software with TT900 (version 
2006, Nonlinear Dynamics). 
 
Results  
Design of Glutamine amber suppressor tRNA 
Normal human glutamine tRNA sequence was modified in the anticodon loop to 
change it to a Glutamine-Amber (GlnUAG) suppressor tRNA (Fig. 6A) and cloned into a 
pGEM-T Easy vector (Promega).  A human U6 promoter was cloned upstream of the 
suppressor tRNA gene to enhance its expression (Fig. 6B). A multimeric construct of 
GlnUAG suppressor tRNA (without an external U6 promoter) was cloned into the pGEM-T 
Easy vector as described in the methods section (Fig. 6C). A enhanced GFP gene carrying an 
introduce amber premature termination codon at the third codon position was used as a 
reporter gene to evaluate the suppression efficacy of various GlnUAG constructs. Due to the 
47 
 
 
UAG amber mutation in the GFP transcripts, GFP protein is not produced in cells. However, 
in the presence of a functional GlnUAG suppressor tRNA, the mutant GFP mRNAs is 
translated into full length protein. The mutant GFP (SEGFP) was cloned into a lentiviral 
vector to design the pLSEGAIN vector. Plates of 293 cells were transduced with the 
pLSEGAIN vector and then selected with G418 to establish a 293 cell line (293/LSEGAIN) 
that expressed mutated GFP transcripts. 
U6 enhanced suppressor tRNA has higher suppression efficacy 
293/LSEGAIN cells did not express detectable GFP in the absence of a suppressor 
tRNA (Fig. 7A). The GlnUAG suppressor tRNA recognizes TAG stop codon in SEGFP 
transcripts and inserts a Glutamine amino acid residue, thereby allowing read through during 
translation. When GlnUAG suppressor tRNA was transfected into 293/LSEGAIN cells, low 
GFP expression was observed (Fig. 7B). But when 293/LSEGAIN cells were transfected 
with a U6GlnUAG suppressor tRNA, GFP expression (analyzed by FACS) increased 
significantly (p-value<0.001). These results show that the U6GlnUAG suppressor tRNA 
construct possesses higher suppression efficacy relative to the GlnUAG suppressor tRNA 
construct lacking a U6 promoter. 
Previously, Buvoli et al. had showed that when multimers of suppressor tRNA genes 
are used to amplify the number of suppressor tRNA transcripts in a cell, the suppression 
efficacy increases significantly (Buvoli, Buvoli et al. 2000). Our initial experiments 
demonstrated that in the system we employed, U6GlnUAG suppressor tRNA constructs have 
higher suppression efficacy. To investigate further, multimers of GlnUAG suppressor tRNA 
were compared to one copy of U6GlnUAG suppressor tRNA to see if the latter had an higher 
suppression efficacy. For this purpose, 293/LSEGAIN cells were transfected with plasmids 
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carrying either multimers of GlnUAG suppressor tRNA or plasmids carrying one copy of 
U6GlnUAG tRNA. 
In our experimental design, our objective was to enhance suppression at two different 
levels. One was to express functional NSTs in a greater population of cells. We further 
intended to increase suppression of nonsense mutations in each of these cells expressing 
suppressor tRNAs. Therefore, the current study was designed such that the FACS results 
would specify the percentage of cells where the suppressor tRNA is functional (percent of 
GFP positive cells) and the suppression efficacy in these cells can be estimated by measuring 
the GFP intensity of the cells (FITC-A mean of cells expressing GFP).  
FACS analysis of 293/LSEGAIN cells transfected with various suppressor tRNA 
constructs revealed some interesting results. When a single U6GlnUAG suppressor tRNA 
was used for suppression of amber mutations in 293/ LSEGAIN cells, the suppressor tRNA 
was functional in as many cells as the multimers of GlnUAG tRNA without U6 promoter 
(Fig. 13) but with twice the suppression efficacy (Fig. 14). GFP intensity doubled when 
U6GlnUAG was used to suppress the nonsense mutations in the SEGFP transcripts. These 
results showed that U6 GlnUAG tRNA can be expressed in more cells and with a higher 
suppression efficacy.  In addition, when multimers of U6GlnUAG suppressor tRNAs were 
used, the data demonstrates clearly that the suppression efficacy increases with the increase 
in number of copies of U6 enhanced GlnUAG suppressor tRNAs in a cell (Fig. 8C). Thus, 
the data here show that U6 promoter enhanced suppressor tRNAs have significantly higher 
suppression efficacies. 
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Suppression of amber mutation in primary astrocytes derived from SEGFP mice 
An effective suppressor tRNA designed for gene therapy should have the ability to 
suppress nonsense mutations in various nuclear genes. Having established that U6 promoter 
enhanced suppressor tRNAs have better suppression efficacy in transient transfections, it was 
important to verify if similar suppression of a stable, nuclear transcript was possible. To 
verify this, primary cells of SEGFP transgenic mice (Ro and Rannala 2004) were employed. 
SEGFP mice were designed to carry SEGFP genes with a TAG mutation at the third codon 
position, and, as a result, none of the cells from these mice express detectable GFP protein.  
Primary astrocytes were isolated from SEGFP mice as described earlier in this study. 
Although these astrocytes do not express GFP, they should express full length GFP in the 
presence of an effective and functional suppressor tRNA. Various GlnUAG constructs were 
transfected into primary astrocytes to verify if they could suppress the nonsense mutation 
GFP mRNA and result in full length GFP protein expression. When 8 copies of U6GlnUAG 
suppressor tRNA were transfected into primary SEGFP mouse astrocytes, the nonsense 
mutation in GFP transcripts was suppressed and functional GFP protein was expressed (Fig. 
9B). Similar correction was not detected when multimers of GlnUAG suppressor tRNAs 
without an external U6 promoter were expressed in SEGFP mouse astrocytes (Fig. 9C). 
Although multimers of GlnUAG tRNAs did suppress a PTC during transfections of 293 cells, 
they did not demonstrably suppress a nonsense mutation in the GFP mRNA in SEGFP 
transgenic mouse astrocytes. Hence, these results suggest that U6GlnUAG may be employed 
to effectively suppress a stop codon mutation in primary cells of SEGFP mice. 
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Constitutive and stable expression of suppressor tRNA in 293 cells 
It was previously reported that long term expression of NST can be detrimental to cell 
survival (Hudziak, Laski et al. 1982). Stable expression of NST was shown to cause sterility 
in Drosophila (Laski, Ganguly et al. 1989). However, tobacco plants constitutively 
expressing suppressor tRNA are normal (Choisne, Martin-Canadell et al. 1997). Some 
researchers attribute toxicity of suppressor tRNAs to their capability to read through normal 
stop codons which may turn normal proteins into longer, abnormal proteins and drastically 
alter their regular cellular functions (Atkinson and Martin 1994). In this context, it is 
important to study the effects of stable suppressor tRNA expression before suppressor tRNAs 
are used in gene therapy. Therefore, a 293 cell line stably expressing the GlnUAG suppressor 
tRNA was established to study the effects of GlnUAG suppressor tRNA on protein 
expression patterns.  
To establish the stable cells, 293/LSEGAIN cells were transfected with linearized U6-
GlnUAG-8 suppressor tRNA construct and, after 48 hr, GFP positive cells were sorted by 
FACS. The GFP positive cells were further cultured and, after two more rounds of sorting for 
GFP positive cells, a stable 293 cell line constitutively expressing a GlnUAG nonsense 
suppressor tRNA was established. Fluorescence microscope images (Fig. 10A & 10B) and 
Western analysis (Fig. 10C) confirmed that 293/LSEGAIN /U6GlnUAG-8 cells produce full 
length GFP protein. Presence of the SEGFP gene and U6GlnUAG genes in the 293 stable 
cells was verified by PCR analysis (Fig. 11A & 11B). Using a similar procedure, the 
GlnUAG suppressor tRNA was also stably expressed in A549 cells (data not shown here). 
These results indicate that GlnUAG suppressor tRNA can be stably expressed in and function 
to correct the PTC mutation in cells. 
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Proteomic changes in 293 cells stably expressing a GlnUAG suppressor tRNA 
293 cells stably expressing a GlnUAG tRNA exhibited normal growth characteristics 
when passaged over a 3 month period without any loss of GFP expression. However, if 
suppressor tRNAs do cause random read through of many transcripts, 293 cells expressing 
GlnUAG tRNA may have significant proteomic changes that are not detected by changes in 
cell growth. Readthrough of regular stop codons may result abnormally long proteins 
depending on the extent and efficiency of the read through. To examine if any proteomic 
changes occurred in cells that constitutively express suppressor tRNA, whole cell proteins 
from cells with and without any suppressor tRNA expression were isolated and were 
analyzed by 2D gel electrophoresis (Fig. 12). The results are summarized in Table 4.   
All proteomic differences in the protein samples were analyzed by Progenesis 
Discovery software. These results indicated that out of 875 proteins that were compared, 
there were a total of 13 unique protein spots in 293 cells expressing GlnUAG tRNA and 5 
unique protein spots in 293 cells without GlnUAG tRNA suppressor tRNA. When protein 
expression levels were compared, 293 cells expressing GlnUAG tRNA had 4% of total 
proteins that had higher expression compared to 293 cells without any suppressor tRNA 
expression.  
Sometimes misfolding of proteins or minute changes in protein expression in cells 
can be detrimental to cells. Suppressor tRNA may read through normal stop codons and 
result in proteins that are elongated at the C-terminal. This may in turn lead to protein 
misfolding. Such misfolded and abnormal proteins in a cell leads to increased heat shock 
protein (HSP) expression (Liberek, Lewandowska et al. 2008). HSPs are molecular 
chaperones that are expressed by the cell in response to internal or external stress stimuli (Li 
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and Srivastava 2004). Internal stress caused by misfolded or abnormal proteins also increases 
expression of Hsp70 protein (Agashe and Hartl 2000). To verify if stable expression of 
GlnUAG suppressor tRNA increases heat shock protein expression, we extracted proteins 
from 293 cells with and without GlnUAG suppressor tRNA expression and the Hsp70 
protein level in these cells were compared. Western analysis indicated, that the 293 cells 
expressing GlnUAG tRNA have similar Hsp70 protein levels as 293 cells without any 
suppressor tRNAs (data not shown). Although these results may indicate that, continuous 
expression of suppressor tRNA in cells does not induce adverse effects in the cells, further 
study is required to demonstrate overall safety of suppressor tRNAs.  
 
Discussion                        
Suppressor tRNAs have been previously suggested as one of approaches for the gene 
therapy of genetic diseases caused by nonsense mutations (Temple, Dozy et al. 1982; 
Panchal, Wang et al. 1999) . But some data has indicated that NSTs may be toxic to cells 
(Hudziak, Laski et al. 1982; Laski, Ganguly et al. 1989), while in other studies suppressor 
tRNA mediated toxicity was not observed (Temple, Dozy et al. 1982; Panchal, Wang et al. 
1999) . In an effort to develop suppressor tRNAs for gene therapy of nonsense mutation 
associated diseases, some of the crucial aspects of suppressor tRNA mediated gene therapy 
were evaluated in this study. The data here showed that U6 enhanced suppressor tRNAs have 
increased suppression efficacies, can correct stop codon mutations in primary cells, and , can 
be stably expressed in 293 cells without any drastic changes in the proteomic expression 
patterns of the cells. 
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Various strategies have been used to increase expression of suppressor tRNAs in cells 
(Drabkin, Park et al. 1996; Park and RajBhandary 1998; Buvoli, Buvoli et al. 2000). 
Multimers of NSTs increase amounts of suppressor tRNA transcribed in a cell, that in turn, 
compete efficiently with amino acyl synthetases and translation termination factors. These 
factors can contribute to eventual increase in suppression efficacy; but this strategy is 
successful only if the internal promoter of the suppressor tRNA is not differentially 
expressed in a given cell type. If the promoter of a NST is inactive in a cell, which is a 
distinclty possible  considering that suppressor tRNAs are derived from cognate tRNAs and 
almost all tRNAs are spatially and temporally regulated (Kondo, Hodgkin et al. 1988; Li, 
Linning et al. 1998; Srinivasan and Gopinathan 2001; Dittmar, Goodenbour et al. 2006), 
multimers of the suppressor tRNA may not improve the suppression efficacy to a great 
extent. To address this issue we decided to test different approaches that increase efficacy of 
suppressor tRNA. As Lai et al. have previously shown, the presence of a constitutively active 
housekeeping gene promoter like a human U6 promoter, upstream of a tRNA gene, increases 
the tRNA transcription (Lai, Weng et al. 2004). A similar strategy to increase the suppressor 
tRNA efficacy by using the U6 promoter to enhance GlnUAG transcription was employed 
here to demonstrate that U6 promoter enhanced suppressor tRNAs have higher suppression 
efficacies than GlnUAG suppressor tRNA without an external promoter.  
The U6 promoter enhanced suppressor tRNA constructs can be readily adapted for 
expression through a variety of viral vectors. This study also shows that U6GlnUAG 
suppressor tRNA can effectively suppress a nonsense mutation in primary cells of SEGFP 
transgenic mice, while any suppression with multimers of GlnUAG suppressor tRNAs 
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without U6 promoter was not detectable in our experiments. These data are significant since 
the target cells for gene therapy will be nontransformed normal tissue or stem cells. 
One of the objectives of this study was to examine the effects of stable expression of 
suppressor tRNAs in mammalian cells. There is a possibility that, suppressor tRNAs read 
through normal stop codons, resulting in abnormal elongation of cellular proteins – some of 
these modifications may be detrimental to cells. These potential adverse effects may not be 
effects only on growth and survival of cells. For instance, the most common nondeletional 
α−thalassemia is caused due to a mutation that allows read through of normal stop codons in 
the transcripts (Cooper 1993; Conne, Stutz et al. 2000). Read through of a normal stop codon 
can also in turn shorten the 3’UTR length in transcripts(Tanguay and Gallie 1996). Recent 
research has shown that a shortened 3’UTR in mRNAs, that is a result of normal stop codon 
read through, affects mRNA stability and thereby disrupts normal cellular functions. 
However, the only comprehensive study previously done to study the effects of suppressor 
tRNAs on read through of normal stop codons suggested that the proteomic changes in 
eukaryotic cells in presence of suppressor tRNAs are not very significant (Bienz, Kubli et al. 
1981). 
Comparison of proteins from 293 cells expressing GlnUAG tRNA to proteins from 
293 cells without suppressor tRNAs did indicate some differences in proteomic patterns. To 
put these results in perspective, when Xenopus ooctyes were injected with normal tRNATrp, 
about 3%  of the proteins showed differences  (Bienz, Kubli et al. 1981).  If readthrough 
occurred universally at the UAG stop codon, a much larger difference would be expected as 
26% of all human transcripts have UAG as regular stop codons. Our data therefore indicate 
that the proteomic changes seen in 293 cells stably expressing GlnUAG tRNAs may be 
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modestly significant. A similar experiment performed to study read through effects of 
different suppressor tRNAs (Bienz, Kubli et al. 1981) suggested that there is no significant 
read through of cellular proteins in the presence of suppressor tRNAs. In addition, 
comparison of Hsp70 protein levels in 293 cells with and without GlnUAG suppressor tRNA 
expression suggests that the few changes in protein expression observed in 293 cells stably 
expressing GlnUAG suppressor tRNA does not put the cells under any added duress. 
Although these are encouraging findings for suppressor tRNA mediated gene therapy 
designs, further in depth study of suppressor tRNA read though effects on mammalian cells 
is highly warranted.  
It is possible that the toxic effects of suppressor tRNAs depend on a combination of 
several factors – namely, the type of nonsense suppressor tRNA, its suppression efficacy, 
how efficiently they compete with cognate tRNAs, number/type of stop codons downstream 
of the naturally occurring stop codon, strength of the stop codon, and the effect of proteins 
that have been elongated by read through of their normal stop codons. It is important to note 
that a GlnUAG tRNA can recognize less than 1/3 of all stop codons in the cellular mRNA 
(Atkinson and Martin 1994). All these factors might have facilitated in stably expressing a 
GlnUAG tRNA in 293 cells. At this point, it can only be speculated that certain suppressor 
tRNAs may be toxic only when expressed at very high levels. For an ideal NST mediated 
gene therapy protocol, suppressor tRNAs should be expressed at reasonable levels where 
they are functionally relevant to suppress a mutation but not too high to cause random read 
through of normal cellular proteins. In future studies, the cellular target and the specific 
suppressor tRNA(s) need to be examined in greater detail. Such studies will be a prerequisite 
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part of the safety data necessary before clinical applications of this technology are 
considered. 
Apart from suppressor tRNAs, aminoglycosides have been used for PTC read through 
(Wagner, Hamed et al. 2001; Wilschanski, Yahav et al. 2003; Lai, Chun et al. 2004; James, 
Raut et al. 2005; Hamed 2006). Aminoglycosides are a class of antibiotics that act on the 
decoding site of ribosomes during translation and facilitate insertion of amino acids at stop 
codons by nonspecific cognate tRNAs (Palmer, Wilhelm et al. 1979; Burke and Mogg 1985). 
There are several different types of aminoglycosides that are used for nonsense codon read 
through (Diop, Chauvin et al. 2007), some of which have even proceeded to clinical trials 
(Bidou, Hatin et al. 2004; Hamed 2006; Clancy, Rowe et al. 2007). In light of these reports, it 
is vital to note that compared to aminoglycosides, suppressor tRNAs have much higher 
suppression efficacies (Diop, Chauvin et al. 2007).  
The other major advantage of using NSTs instead of aminoglycosides is that the latter 
cannot read through stop codons when NMD (Nonsense mediated mRNA decay) pathway 
degrades mRNAs containing nonsense mutations (Linde, Boelz et al. 2007). It has been 
shown in clinical trials that the activity of NMD determines patients’ response to treatment 
with aminoglycosides (Linde, Boelz et al. 2007). In some patients afflicted with diseases 
caused due to PTC mutations, NMD degrades transcripts with premature stop codon 
mutations, and, in such cases, aminoglycosides have no or limited therapeutic utility. In 
contrast, suppressor tRNAs stabilize the mRNAs with nonsense mutations resulting in 
inhibition of NMD (Gozalbo and Hohmann 1990). Finally, there are reports of ototoxicity 
and nephrotoxicity associated with long term use of most aminoglycosides reported to date 
(Warady, Reed et al. 1993; de Jager and van Altena 2002). Hence, there is a case for 
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exploring the possibility of using suppressor tRNA mediated gene therapy as a viable option 
for gene therapy of PTC induced genetic diseases. Another possibility is that NSTs can be 
used along with aminoglycosides for better PTC suppression with lesser side effects.  
Another area of research where U6 promoter enhanced suppressor tRNAs may prove 
to be valuable is development of unnatural amino acids. Unnatural amino acids are an 
exciting development (Wang, Xie et al. 2006) with a promising future, especially in design 
and synthesis of new therapeutic drugs. Unnatural amino acids can be incorporated into 
normal peptides more efficiently using suppressor tRNAs. Currently, unnatural amino acids 
are inserted into proteins either chemically or by using an orthogonal tRNA-aaRSs pair 
(Wang and Schultz 2001; Ryu and Schultz 2006). It was also reported that the efficacy of 
incorporation of unnatural amino acids increases linearly with the amount of suppressor 
tRNA used (Rodriguez, Lester et al. 2006). Hence U6 promoter enhanced suppressor tRNAs 
may prove to be more efficient for insertion of unnatural amino acids into various proteins.  
In conclusion, our results suggest that U6 promoter enhanced GlnUAG suppressor 
tRNAs have higher suppression efficacies and can suppress a defined premature stop codon 
mutation in both transformed and normal cells with high efficiency. These data present a 
basis for further study of U6 promoter enhanced suppressor tRNAs in specific PTC mediated 
disease models. 
Acknowledgements 
We would like to thank NewLink Genetics Corp. for financial support of this project,  
Dr. Nicholas Vahanian, Dr. Won Bin Young and Dr. Mario Mautino for intellectual and 
critical support, Dr. Serguei Kisselev for FACS analysis, and Dawn Bertrand for taking care 
of the SEGFP transgenic mice. 
58 
 
 
References 
Agashe, V. R. and F. U. Hartl (2000). "Roles of molecular chaperones in cytoplasmic protein 
folding." Semin Cell Dev Biol 11(1): 15-25. 
Atkinson, J. and R. Martin (1994). "Mutations to nonsense codons in human genetic disease: 
implications for gene therapy by nonsense suppressor tRNAs." Nucleic Acids Res 22(8): 
1327-34. 
Atkinson, J. and R. Martin (1994). "Mutations to nonsense codons in human genetic disease: 
implications for gene therapy by nonsense suppressor tRNAs." Nucleic acids research 22(8): 
1327-34. 
Bidou, L., I. Hatin, et al. (2004). "Premature stop codons involved in muscular dystrophies 
show a broad spectrum of readthrough efficiencies in response to gentamicin treatment." 
Gene therapy 11(7): 619-27. 
Bienz, M., E. Kubli, et al. (1981). "Usage of the three termination codons in a single 
eukaryotic cell, the Xenopus laevis oocyte." Nucleic acids research 9(15): 3835-50. 
Burke, J. F. and A. E. Mogg (1985). "Suppression of a nonsense mutation in mammalian 
cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin." Nucleic acids 
research 13(17): 6265-72. 
Buvoli, M., A. Buvoli, et al. (2000). "Suppression of nonsense mutations in cell culture and 
mice by multimerized suppressor tRNA genes." Mol Cell Biol 20(9): 3116-24. 
Capecchi, M. R., R. A. Haar, et al. (1977). "The isolation of a suppressible nonsense mutant 
in mammalian cells." Cell 12(2): 371-81. 
Capecchi, M. R., S. H. Hughes, et al. (1975). "Yeast super-suppressors are altered tRNAs 
capable of translating a nonsense codon in vitro." Cell 6(3): 269-77. 
Cavener, D. R. and S. C. Ray (1991). "Eukaryotic start and stop translation sites." Nucleic 
Acids Res 19(12): 3185-92. 
Choisne, N., A. Martin-Canadell, et al. (1997). "Transactivation of a target gene using a 
suppressor tRNA in transgenic tobacco plants." Plant J 11(3): 597-604. 
Clancy, J. P., S. M. Rowe, et al. (2007). "No detectable improvements in cystic fibrosis 
transmembrane conductance regulator by nasal aminoglycosides in patients with cystic 
fibrosis with stop mutations." American journal of respiratory cell and molecular biology 
37(1): 57-66. 
Conne, B., A. Stutz, et al. (2000). "The 3' untranslated region of messenger RNA: A 
molecular 'hotspot' for pathology?" Nat Med 6(6): 637-41. 
Cooper, D. N. (1993). "Human gene mutations affecting RNA processing and translation." 
Ann Med 25(1): 11-7. 
de Jager, P. and R. van Altena (2002). "Hearing loss and nephrotoxicity in long-term 
aminoglycoside treatment in patients with tuberculosis." Int J Tuberc Lung Dis 6(7): 622-7. 
59 
 
 
Diop, D., C. l. Chauvin, et al. (2007). "Aminoglycosides and other factors promoting stop 
codon readthrough in human cells." Comptes rendus biologies 330(1): 71-9. 
Dittmar, K. A., J. M. Goodenbour, et al. (2006). "Tissue-specific differences in human 
transfer RNA expression." PLoS Genet 2(12): e221. 
Drabkin, H. J., H. J. Park, et al. (1996). "Amber suppression in mammalian cells dependent 
upon expression of an Escherichia coli aminoacyl-tRNA synthetase gene." Molecular and 
cellular biology 16(3): 907-13. 
Ganoza, M. C. and J. K. Tomkins (1970). "Polypeptide chain termination in vitro: 
competition for nonsense codons between a purified release factor and suppressor tRNA." 
Biochem Biophys Res Commun 40(6): 1455-63. 
Gieg‚, R., M. Sissler, et al. (1998). "Universal rules and idiosyncratic features in tRNA 
identity." Nucleic acids research 26(22): 5017-35. 
Gozalbo, D. and S. Hohmann (1990). "Nonsense suppressors partially revert the decrease of 
the mRNA level of a nonsense mutant allele in yeast." Curr Genet 17(1): 77-9. 
Hamed, S. A. (2006). "Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and 
Duchenne muscular dystrophy." IDrugs : the investigational drugs journal 9(11): 783-9. 
Hudziak, R. M., F. A. Laski, et al. (1982). "Establishment of mammalian cell lines containing 
multiple nonsense mutations and functional suppressor tRNA genes." Cell 31(1): 137-46. 
James, P. D., S. Raut, et al. (2005). "Aminoglycoside suppression of nonsense mutations in 
severe hemophilia." Blood 106(9): 3043-8. 
Janzen, D. M. and A. P. Geballe (2004). "The effect of eukaryotic release factor depletion on 
translation termination in human cell lines." Nucleic Acids Res 32(15): 4491-502. 
K”hrer, C., E. L. Sullivan, et al. (2004). "Complete set of orthogonal 21st aminoacyl-tRNA 
synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three 
different termination codons in an mRNA in mammalian cells." Nucleic acids research 
32(21): 6200-11. 
Kondo, K., J. Hodgkin, et al. (1988). "Differential expression of five tRNA(UAGTrp) amber 
suppressors in Caenorhabditis elegans." Mol Cell Biol 8(9): 3627-35. 
Kuzmiak, H. A. and L. E. Maquat (2006). "Applying nonsense-mediated mRNA decay 
research to the clinic: progress and challenges." Trends in molecular medicine 12(7): 306-16. 
Lai, C.-H., H. H. Chun, et al. (2004). "Correction of ATM gene function by aminoglycoside-
induced read-through of premature termination codons." Proceedings of the National 
Academy of Sciences of the United States of America 101(44): 15676-81. 
Lai, D., S. Weng, et al. (2004). "Small antisense RNA to cyclin D1 generated by pre-tRNA 
splicing inhibits growth of human hepatoma cells." FEBS Lett 576(3): 481-6. 
Lai, D., S. Weng, et al. (2004). "Small antisense RNA to cyclin D1 generated by pre-tRNA 
splicing inhibits growth of human hepatoma cells." FEBS letters 576(3): 481-6. 
60 
 
 
Laski, F. A., S. Ganguly, et al. (1989). "Construction, stable transformation, and function of 
an amber suppressor tRNA gene in Drosophila melanogaster." Proceedings of the National 
Academy of Sciences of the United States of America 86(17): 6696-8. 
Laski, F. A., S. Ganguly, et al. (1989). "Construction, stable transformation, and function of 
an amber suppressor tRNA gene in Drosophila melanogaster." Proc Natl Acad Sci U S A 
86(17): 6696-8. 
Li, L., R. M. Linning, et al. (1998). "Differential expression of individual suppressor 
tRNA(Trp) gene gene family members in vitro and in vivo in the nematode Caenorhabditis 
elegans." Molecular and cellular biology 18(2): 703-9. 
Li, Z. and P. Srivastava (2004). "Heat-shock proteins." Curr Protoc Immunol Appendix 1: 
Appendix 1T. 
Liberek, K., A. Lewandowska, et al. (2008). "Chaperones in control of protein 
disaggregation." EMBO J 27(2): 328-35. 
Linde, L., S. Boelz, et al. (2007). "Nonsense-mediated mRNA decay affects nonsense 
transcript levels and governs response of cystic fibrosis patients to gentamicin." The Journal 
of clinical investigation 117(3): 683-92. 
McCaughan, K. K., C. M. Brown, et al. (1995). "Translational termination efficiency in 
mammals is influenced by the base following the stop codon." Proc Natl Acad Sci U S A 
92(12): 5431-5. 
Nair, V. (2008). "Retrovirus-induced oncogenesis and safety of retroviral vectors." Curr Opin 
Mol Ther 10(5): 431-8. 
O'Farrell, P. H. (1975). "High resolution two-dimensional electrophoresis of proteins." J Biol 
Chem 250(10): 4007-21. 
Palmer, E., J. M. Wilhelm, et al. (1979). "Phenotypic suppression of nonsense mutants in 
yeast by aminoglycoside antibiotics." Nature 277(5692): 148-50. 
Panchal, R. G., S. Wang, et al. (1999). "Partial functional correction of xeroderma 
pigmentosum group A cells by suppressor tRNA." Hum Gene Ther 10(13): 2209-19. 
Park, H. J. and U. L. RajBhandary (1998). "Tetracycline-regulated suppression of amber 
codons in mammalian cells." Mol Cell Biol 18(8): 4418-25. 
Ro, S. and B. Rannala (2004). "A stop-EGFP transgenic mouse to detect clonal cell lineages 
generated by mutation." EMBO reports 5(9): 914-20. 
Rodriguez, E. A., H. A. Lester, et al. (2006). "In vivo incorporation of multiple unnatural 
amino acids through nonsense and frameshift suppression." Proc Natl Acad Sci U S A 
103(23): 8650-5. 
Roy, K. L., H. Cooke, et al. (1982). "Nucleotide sequence of a segment of human DNA 
containing the three tRNA genes." Nucleic Acids Res 10(22): 7313-22. 
Ryu, Y. and P. G. Schultz (2006). "Efficient incorporation of unnatural amino acids into 
proteins in Escherichia coli." Nat Methods 3(4): 263-5. 
61 
 
 
Srinivasan, L. and K. P. Gopinathan (2001). "Differential expression of individual gene 
copies from within a tRNA multigene family in the mulberry silkworm Bombyx mori." 
Insect molecular biology 10(6): 523-30. 
Strasser, B. J. (2006). "A world in one dimension: Linus Pauling, Francis Crick and the 
central dogma of molecular biology." Hist Philos Life Sci 28(4): 491-512. 
Tanguay, R. L. and D. R. Gallie (1996). "Translational efficiency is regulated by the length 
of the 3' untranslated region." Mol Cell Biol 16(1): 146-56. 
Temple, G. F., A. M. Dozy, et al. (1982). "Construction of a functional human suppressor 
tRNA gene: an approach to gene therapy for beta-thalassaemia." Nature 296(5857): 537-40. 
Wagner, K. R., S. Hamed, et al. (2001). "Gentamicin treatment of Duchenne and Becker 
muscular dystrophy due to nonsense mutations." Annals of neurology 49(6): 706-11. 
Wang, L. and P. G. Schultz (2001). "A general approach for the generation of orthogonal 
tRNAs." Chem Biol 8(9): 883-90. 
Wang, L., J. Xie, et al. (2006). "Expanding the genetic code." Annu Rev Biophys Biomol 
Struct 35: 225-49. 
Warady, B. A., L. Reed, et al. (1993). "Aminoglycoside ototoxicity in pediatric patients 
receiving long-term peritoneal dialysis." Pediatr Nephrol 7(2): 178-81. 
Wilschanski, M., Y. Yahav, et al. (2003). "Gentamicin-induced correction of CFTR function 
in patients with cystic fibrosis and CFTR stop mutations." The New England journal of 
medicine 349(15): 1433-41. 
 
62 
 
 
 
 
Figure 6: Design of vectors. 
 (A) – GlnUAG suppressor tRNA. A single nucleotide, ‘G’ in the anticodon loop was 
changed to ‘A’ to convert Gln tRNA to a GlnUAG suppressor tRNA.  (B) – Vector carrying 
U6 promoter enhanced GlnUAG suppressor tRNA. (C) – Multimers of GlnUAG suppressor 
tRNA without any upstream U6 promoter. 
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Figure 7: Comparison of suppression efficacy of GlnUAG suppressor tRNA with and 
without an upstream U6 promoter. 
 (A) – Untransfected 293/LSEGAIN cells expressing mutant GFP only. (B) –293/LSEGAIN 
cells transfected with GlnUAG suppressor tRNA without U6 promoter. (C) – 293/LSEGAIN 
cells transfected with U6GlnUAG suppressor tRNA. (D) – Positive control, 293/LSEGAIN 
cells transfected with normal GFP.  
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Figure 8: Comparison of suppression efficacy of GlnUAG multimers without 
U6 promoter and one copy of GlnUAG with U6 promoter. 
293/LSEGAIN cells were transfected with multimers of GlnUAG suppressor tRNA or with 
plasmids carrying U6GlnUAG tRNA. (A) – 293/LSEGAIN cells transfected with plasmid 
expressing only a single copy of U6GlnUAG tRNA. (B) – 293/LSEGAIN cells transfected 
with plasmid carrying 8 copies of GlnUAG. (C) – 293/LSEGAIN cells transfected with 
plasmid carrying 8 copies of U6GlnUAG.  
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Figure 9: Suppression of amber mutation in SEGFP gene of primary astrocytes derived 
from SEGFP transgenic mice. 
Astrocytes isolated from SEGFP mice were transfected with GlnUAG suppressor tRNA, with 
and without U6 promoter. (A) – Astrocytes transfected with normal GFP. (B) – Astrocytes 
transfected with plasmid carrying U6GlnUAG-8 tRNA. (C) – Astrocytes transfected with 
plasmid expressing GlnUAG-8 tRNA. 
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Figure 10: U6GlnUAG can be stably expressed in 293 cells. 
293/LSEGAIN cells were transfected with U6GlnUAG suppressor tRNA. In presence of the 
suppressor tRNA, these cells express full length GFP. (A) – 293/LSEGAIN cells expressing 
U6GlnUAG-8 suppressor tRNA. (B) – 293/LSEGAIN cells without suppressor tRNA. (C) – 
Western blot for GFP in 293 GlnUAG stable cells. Lane 1 has purified GFP protein. Lane 2 
has proteins from 293/LSEGAIN cells without suppressor tRNA and Lane 3 has proteins 
from 293/LSEGAIN cells expressing GlnUAG suppressor tRNA. (D) – Comparison of 
Hsp70 protein levels in 293/LSEGAIN cells with and without GlnUAG suppressor tRNA. 
Lane 1 has proteins from 293 cells. Lane 2 has proteins from 293 cells expressing SEGFP but 
not suppressor tRNA. Lane 3 has proteins from cells that were stably expressing GlnUAG 
suppressor tRNA. 
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Figure 11: PCR verification of presence of SEGFP and suppressor tRNA in 293 cells 
stably expressing GlnUAG suppressor tRNA. 
(6A) – PCR for presence of SEGFP gene 293 in cells with and without suppressor tRNA. 
(6B) – PCR for presence of GlnUAG suppressor tRNA in 293/U6GlnUAG stable cells. Lane 
1 has DNA from 293/U6GlnUAG stable cells. Lane 2 has DNA from 293 cells without any 
suppressor tRNA. Lane 3 has Plasmid DNA as positive control. Lane 4 has no template. 
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Figure 12: Comparison of protein expression in cells with and without GlnUAG suppressor 
tRNA by 2D gel electrophoresis. (A) – Whole cell proteins from 293 cells without suppressor 
tRNA. (B) – Whole cell proteins from 293 cells stably expressing GlnUAG suppressor tRNA. 
GFP in stable GlnUAG suppressor tRNA cells is shown in gel B. 
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Figure 13: U6 promoter enhanced GlnUAG suppressor tRNA has better expression. 
293/LSEGAIN cells were transfected with various GlnUAG suppressor tRNA constructs. 
The cells were later analyzed by FACS to measure the population of cells expressing full 
length functional GFP. Multiple transfections were performed to compare differences in 
various constructs and the graph here illustrates the results of one such experiment. The 
individual differences were analyzed by two way Anova (p-value <0.001). 
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Figure 14: U6 promoter enhanced GlnUAG suppressor tRNA has higher suppression 
efficacy. 
293/LSEGAIN cells were transfected various GlnUAG constructs and analyzed by FACS for 
the amount of GFP they express in presence of a functional GlnUAG suppressor tRNA. 
Higher FITC-A mean correlates to higher suppression efficacy. For comparing different 
constructs, multiple transfections were performed several times and the graph here illustrates 
the results of one such experiment. All the individual differences were analyzed by two way 
Anova (p-value <0.001). 
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Number Spot pI Mol. Wt. (kDa) 
1 34 5.4 92701 
2 180 5.1 63258 
3 329 4.7 44200 
4 435 5.1 38653 
5 835 5.9 13540 
6 53 8.2 86846 
7 346 5.2 47139 
8 361 8.7 42126 
9 404 5.2 43582 
10 448 8.2 38012 
11 527 7.0 33482 
12 535 5.3 33186 
13 660 6.8 26600 
14 667 7.0 26303 
15 696 8.4 24605 
16 787 6.4 16457 
17 797 7.2 15541 
18 859 7.2 12603 
 
Table 4: Summary of 2D gel electrophoresis results. 
Whole cell protein from 293/LSEGAIN cells with and without GlnUAG suppressor tRNA 
were run on two different 2D gels (2 gels each for each sample) and stained by silver stain. 
Resulting protein spots were compared for their integrated densities by Progenesis Discovery 
software. The table shows unique spots in each protein sample, their pIs and molecular 
weights. Protein spots 1 to 5 were unique to cells without suppressor tRNA and protein spots 
6 to 18 were unique to 293 cells stably expressing GlnUAG suppressor tRNA. 
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Chapter 3 
Initial pilot experiments for in vivo expression of Glutamine-Amber 
suppressor tRNAs using dsAAV2 vectors. 
Koukuntla R1 and Link CJ Jr.1, 2 
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Abbreviations: 
MoMLV – Moloney murine leukemia virus 
VSV G – Vesicular stomatitis virus G protein 
CMV - Cytomegalovirus 
NST – Nonsense Suppressor tRNA. 
GlnUAG – Glutamine UAG (amber) suppressor tRNA. 
PTC – Premature Termination Codon. 
SEGFP – Stop Enhanced Green Fluorescent Protein. 
dsAAV2 – double stranded Adeno-associated Viral Vector. 
Abstract         
Nearly 30% of genetic diseases in humans are a result of nonsense mutations. 
Nonsense suppressor tRNAs (NSTs) recognize these mutations and allow protein synthesis to 
continue through that site. NSTs have been proposed as promising tools for treatment of 
genetic diseases resulting from nonsense mutations. However, issues regarding the efficiency 
of suppressor tRNA targeting, delivery and duration of suppression by NSTs must be 
addressed before suppressor tRNAs can be effectively utilized for gene therapy. In this 
report, initially retroviral and AAV vectors were tested for their ability to carry glutamine 
amber suppressor tRNA (GlnUAG) genes. First, dsAAV2 vectors can carry a GlnUAG tRNA 
(dsAAV2-U6GlnUAG) and be propagated. Second, the efficacy of suppression in vitro was 
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demonstrated by the rescue of the expression of a GFP gene inactivated by an amber 
nonsense mutation in 293 cells by a dsAAV2-U6GlnUAG vector. Finally our initial in vivo 
study here restored full length GFP in one SEGFP mouse and suggests that dsAAV2-
U6GlnUAG vectors injected into SEGFP mouse may result in modest in vivo functional 
correction of a mutant GFP gene.  
Introduction             
Human genetic diseases result from many different mutations, either alone or in 
combination with mis-sense/nonsense point mutations, insertions, deletions, and 
chromosomal translocations/truncations (Hamosh, Scott et al. 2005; Stenson, Ball et al. 
2008). Over one third of these genetic diseases are caused by nonsense mutations (Atkinson 
and Martin 1994). Genetic diseases such as Duchene muscular dystrophy or Cystic fibrosis 
cause serious disabilities or are fatal. Currently, there are very few effective therapeutic 
options for patients suffering from such diseases (Hamed 2006; Kuzmiak and Maquat 2006; 
Linde, Boelz et al. 2007). However, gene therapy is providing some hope for patients 
suffering from severe genetic diseases (Tomanin and Scarpa 2004; Parekh-Olmedo, Ferrara 
et al. 2005).  
Nonsense suppressor tRNAs recognize chain termination or "stop codons" and allow 
for the RNA polymerase II read-through by insertion of a specific amino acid in that site 
(Smith JD 1966; Hirsh and Gold 1971). Although use of suppressor tRNAs for the gene 
therapy of diseases caused by nonsense mutations has been proposed, (Temple, Dozy et al. 
1982), concerns regarding NST toxicity (Hudziak, Laski et al. 1982; Laski, Ganguly et al. 
1989) and low suppression efficacies have limited progress in this area. Nevertheless, several 
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strategies to increase suppressor tRNA efficacy have been developed. Orthogonal expression 
of a suppressor tRNA derived from E.Coli along with the corresponding amino-acyl 
synthetase (aaRS) has been used to increase suppressor tRNA activity in mammalian cells 
(K”hrer, Sullivan et al. 2004). Other researchers have used multimers of suppressor tRNA 
gene constructs to substantially improve suppression efficacy (Buvoli, Buvoli et al. 2000). 
Despite such advances, significant limitations to suppressor tRNA delivery and the efficacy 
of suppression by NSTs, including lack of an efficient viral vector for delivery in vivo, 
remain. To further develop the idea of employing suppressor tRNAs for gene therapy, the 
expression and toxicity problems associated with NSTs were previously addressed  by 
Koukuntla and Link (Koukuntla and Link 2009) who showed that U6 promoter enhanced 
expression of Gln-Amber suppressor tRNAs in 293cells leads to stable expression and higher 
suppression efficacies without apparent toxicity. 
An ideal viral vector system for suppressor tRNA delivery should have the capacity 
to carry multimers of suppressor tRNAs (for expression of suppressor tRNAs at functionally 
relevant levels), be able to transduce a variety of cell types, cause minimal adverse effects, 
provide for stable and long term expression of NSTs and elicit negligible or no immune 
response against the vector. For suppressor tRNAs to be functionally effective, the vector 
must deliver enough suppressor tRNA genes into a cell to compete with cognate tRNAs and 
release factors (Beier and Grimm 2001; Ilegems, Pick et al. 2004). Increased transcription or 
high copy number of suppressor tRNA genes can improve NST expression. In the later 
scenario, high titer viral vector is needed for transduction of cells at high multiplicity of 
infection to transfer large numbers of suppressor tRNA genes into cells (Clancy, Rowe et 
al.).  
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MoMLV (Moloney Murine Leukemia Virus) based retroviral vectors have been used 
for stable and long term expression of transgenes in numerous gene therapy studies 
(Barquinero, Eixarch et al. 2004). More than one-fifth of all the gene therapy clinical trials 
worldwide involve use of MoMLV retroviral vectors 
(http://www.wiley.co.uk/genmed/clinical). AAV based vectors are fast advancing as an 
alternative vector  for gene therapy (Mueller and Flotte 2008). Lack of severe 
immunogenicity, broad range of target diseases, availability of multiple serotypes and 
potential for stable expression of transgenes are some of the advantages of AAV vectors 
(Coura Rdos and Nardi 2007). For testing the AAV system, dsAAV2 vectors were chosen as 
they are likely to be much superior in several aspects when compared to ssAAV2 vectors 
(Wang, Ma et al. 2003). Transgenes expressed through dsAAV2 vectors have better and 
higher expression that begins faster than when ssAAV2 vectors are used for gene transfer 
(Rehman, Wang et al. 2005; Chen, Ma et al. 2007; Sagazio, Xiao et al. 2008). dsAAV2 
vectors also have much higher in vivo vector DNA stability (Rehman, Wang et al. 2005). In 
light of the aforementioned reasons, initial studies were conducted in this study using 
retroviral and AAV vector systems. Our preliminary data with different basic retroviral 
constructs demonstrate adverse effects of suppressor tRNA on retroviral vector titer, while 
AAV vector titers were maintained. Therefore we conducted further in vivo evaluations with 
dsAAV2 vectors expressing GlnUAG suppressor tRNA. 
These initial results described herein indicate that dsAAV2 vectors may carry and 
effectively transfer suppressor tRNAs into cells of SEGFP mice in vivo, leading to the 
suppression of a premature stop codon and partial rescue of GFP expression. However, 
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additional data is required to draw firm conclusions as, at this point, we have successful in 
vivo data from only a single SEGFP mouse.  
Materials and methods         
Vector Construction 
Retroviral vectors: The U6GlnUAG fragment was cut from the pGEM-U6GlnUAG plasmid 
(Koukuntla and Link 2009) with NaeI and NsiI restriction endonucleases. pLEGFP-
U6GlnUAG was generated by inserting the U6GlnUAG fragment into the NaeI/NsiI sites in 
the pLEIN vector (Clontech, Mountain View, CA). U6GlnUAG was excised from the 
pLEGFP-U6GlnUAG vector by SphI and was then inserted into the same SphI site but in an 
inverse orientation to obtain the pLEGFP-U6GlnUAG-Inv vector.  
AAV vectors: The U6GlnUAG fragment was cut from the pGEM-U6GlnUAG plasmid 
(Koukuntla and Link 2009) with MluI and EcoRI restriction endonucleases, endfilled with 
T4 DNA polymerase and cloned in 5’ to 3’ orientation into  a dsAAV2EGFP vector (Applied 
Viromics),cut with SalI / MluI and endfilled) to obtain dsAAV2EGFP-U6GlnUAG. Finally, 
multimers of U6GlnUAG (3 copies) were cloned into a dsAAV2 shuttle vector to generate 
dsAAV2-U6GlnUAG-3 vectors. A CMV promoter driven EGFP  fragment from pGEM-
EGFP (kindly provided by Dr. Jay Ramsey, NewLink Genetics, Ames, Iowa) was excised by 
BamHI / NheI restriction endonucleases and ligated into the dsAAV2 shuttle vector (Applied 
Viromics, Fremont, CA)  to generate dsAAV2EGFP. 
SV Minipreps (Promega, Madison, WI) were employed for DNA Mini-preps, and 
GenElute HP Endotoxin-Free kits (Sigma, St.Louis, MO) were used for Maxi preps. 
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Cell culture 
293 cells (ATCC, Manassas, VA) and 293GP cells (Clontech) were cultured in 
DMEM (Invitrogen, Carlsbad, CA) with 10% FBS (Invitrogen), 2 mM L-Glutamine 
(Invitrogen, Carlsbad, CA), at 37oC and 5% CO2. 
Retrovirus production and transduction 
293GP vector packaging cells (293 cells expressing the MoMLV retroviral gag and 
pol genes) were cultured in 10 cm Biocoat plates (BD Biosciences, San Jose, CA), and were 
transfected with respective retroviral vectors and VSG G (Clontech) using Lipofectamine 
(Invitrogen). Supernatant was collected after 60 hr, filtered using a 0.45 µm filter (Fisher 
Scientific, Pittsburgh) and stored at -80oC until use. Transductions were performed on 5x105 
293 cells cultured on six well plates. Retroviral vectors were added to 293 cells at select 
dilutions. Retroviral vectors were tittered by quantifying GFP expression. Transfections and 
transductions for comparing various retroviral constructs were performed in triplicate. The 
differences in retroviral vector titers were statistically analyzed by ANOVA. 
dsAAV2 production and transduction 
For small-scale viral vector production, dsAAV2 shuttle vector(s) with transgenes 
were cotransfected with pRep-cap and pHelper plasmids (Applied Viromics) into 293 cells 
(plated in 10 cm dishes) using Lipofectamine (Invitrogen). Three days post-transfection, cells 
were collected and lysed by 3 cycles of freezing at -80oC and thawing at 37oC to release the 
virus. Cell lysate was clarified by centrifugation at 3500 x g, 4oC for 20 min, and filtered 
through a 0.22 µm filter (Fisher Scientific). For transduction, 293 cells were cultured in 12 
well plates at 105 cells per well, and select dilutions of viral vectors were added to the cells. 
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High titer dsAAV2EGFP and dsAAV2-U6GlnUAG-3 viral vectors were prepared by 
Applied Viromics.  
Mouse injections 
For in vivo experiments, high titer dsAAV2 vectors at select MOIs were injected into 
the tail veins of anesthetized 4 to 6 week old transgenic SEGFP mice (Table 1). SEGFP mice 
were a kind gift from Dr. Simon Ro (University of Alberta, Canada). These mice carry a GFP 
gene that has TAG stop codon introduced between the third and fourth codons. Because of 
the premature stop codon in the GFP gene, full length GFP is not produced in SEGFP mice. 
dsAAV2 viral vectors of different volumes or vectors diluted in saline to 10% of the body 
weight of each mouse were injected into the mouse tail vein.  
Tissue processing 
Select tissues from mice were collected at 12 weeks post-infection. Tissues were 
immediately frozen in liquid nitrogen (and stored at -80oC) or preserved with a 2 hr 
incubation in fixative composed of 4% formalin, 7% picric acid and 10% sucrose. Fixed 
tissues were mounted in OCT media (Fisher Scientific) and stored at -80oC. Eight µm 
cryosections from these tissues were stained with hematoxylin and eosin for microscopic 
analysis. Frozen tissues were also homogenized with Trizol (Invitrogen) according to the 
manufacturer’s instructions for extraction of DNA, RNA, and proteins. 
PCR and RT-PCR 
Total DNA extracted from mouse tissues was used as a template for PCR. For 
detection of dsAAV2EGFP vector DNA, SEGFP-F2 (5’ atggtgtagagcaagggcgagg 3’) and 
PolyA1 (5’ ctgcattctagttgtggtttgtcca 3’) primers were used. dsAAV2-U6GlnUAG-3 was 
detected with the primers preseq-2 (5’ctggcgaaagggggatgtgctgc 3’) and RTUAG-3 
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(5’aatggttagcactctggactcta 3’). Trizol and DNase I (Ambion, Austin, Texas) were used to 
extract and generate DNA-free RNA from tissues. RT-PCR for detection of GlnUAG tRNA 
transcripts was performed with the same primer set used for PCR. As a RT-PCR RNA 
control, GAPDH primers were used (GAPDH-S: tgatgacatcaagaaggtggtgaag and GAPDH-
AS: tccttggaggccatgtgggccat). All primers/oligos used in this study were obtained from 
IDTDNA, Coralville, IA. PCR was performed using Platinum PCR supermix (Invitrogen) 
and RT-PCR was performed with the Superscript III kit (Invitrogen) and a MJ Research 
PTC-200 Peltier thermal cycler. 
Western analysis  
Mouse tissue protein was extracted using Trizol (Invitrogen). Briefly, about 100 mg 
frozen mouse tissues was homogenized in 3.0 ml of Trizol with a tissue tearor (Biospec, 
Racine, WI). After RNA and DNA extraction from these samples, proteins were precipitated 
with 0.8 volumes of isopropanol and washed 4X with 0.3 M guanidine-HCl in 95% ethanol. 
The protein pellet was dissolved in 1% SDS in water and concentration was measured using 
a BCA kit (Pierce). Proteins (10 µg/lane) were fractionated using 4-12% NuPage Novex Bis-
Tris gels (Invitrogen). Proteins were then transferred to a PVDF membrane (Invitrogen), 
blocked overnight at 4oC with 3% human serum albumin (HSA) in PBST (1X Phosphate 
Buffered Saline Tween-20). GFP was detected using 1:3000 anti-GFP antibodies (anti-GFP, 
sc-8334, Santa Cruz Biotechnology) for 1 hr at room temperature and visualized with 
1:25,000 goat anti-rabbit IgG HRP conjugate (sc-20044, Santa Cruz Biotechnology). 
SuperSignal West Femto Chemiluminescent Substrate (Pierce) and Kodak Biomax light film 
were used to develop and visualize the signals. 
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FACS and microscopy 
After transfections or transductions, cells were harvested with trypsin (Gibco), 
washed once with PBS, and analyzed or sorted on a BD FACSVantage SE flow cytometry 
system and BD FACSDiVa option. Cells were imaged with a Zeiss Axioplan II compound 
microscope equipped with an AxioCam HRC digital camera.  
Results           
Vector design 
Retroviral and dsAAV2 vectors were chosen for the current study because these are 
well established vector systems that can be used for long-term in vivo gene expression 
(Gardlik, Palffy et al. 2005). Previous studies have shown that U6 promoter enhanced 
suppressor tRNAs have higher suppression efficacies than NSTs without an external  U6 
promoter (Koukuntla and Link 2009). Therefore similar U6 promoter enhanced GlnUAG 
suppressor tRNA genes in retroviral and AAV vector backgrounds were tested in this study 
for their ability to facilitate the suppression of nonsense mutations in vitro and in vivo. 
Ideally, suppressor tRNA genes should not interfere with viral vector production or ability to 
transduce different cell types. 
MoMLV based retroviral vectors were chosen for this study as they are one of the 
preferred retroviral vectors for gene delivery into different cell types (Barquinero, Eixarch et 
al. 2004). To test if retroviral vectors are functionally efficient carriers of U6GlnUAG 
suppressor tRNA genes, GFP reporter gene expression was measured in cells transduced with 
retroviral vectors containing a normal GFP reporter gene or GFP and copies of U6GlnUAG 
tRNA genes. Similar GFP levels would indicate that transduction and expression of encoded 
genes is not adversely effected by the inclusion of the suppressor tRNA genes. GFP was 
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cloned into a retroviral vector (pLEIN, Clontech) (Fig. 15A) along with one copy of 
U6GlnUAG tRNA, either in the coding (pLEGFP-U6GlnUAG, Fig. 15B) or antisense 
orientation (pLEGFP-U6GlnUAG-Inv, Fig. 15C). The functional titer of the retroviral 
constructs expressing the GFP gene within transduced 293 cells titer was 1.2x106 IP/ml (Fig. 
16). In contrast, 293 cells transduced with either the pLEGFP-U6GlnUAG or pLEGFP-
U6GlnUAG-Inv vectors demonstrated reduced titers of 7.5x103 IP/ml and 1.62x104 IP/ml 
respectively. Therefore, the data demonstrate for the specific retroviral constructs tested that 
the presence of the U6GlnUAG tRNA strongly interferes with vector titer. 
To test the AAV vector system, GFP reporter gene expression was compared between 
cells transduced with AAV vectors containing a normal GFP reporter gene or GFP gene and 
copies of U6GlnUAG tRNA genes. As described for the retroviral system, similar GFP levels 
would indicate that transduction and expression of encoded genes is not adversely effected 
by the inclusion of the suppressor tRNA genes. CMV promoter-driven GFP and U6GlnUAG 
suppressor tRNA genes were cloned into a dsAAV2 shuttle vector (Fig.15D). One copy of 
U6GlnUAG was then cloned into the dsAAV2EGFP vector (Fig. 15E). Titers of vectors with 
GFP and with both GFP and U6GlnUAG NST were compared. FACS analysis shows that 
inclusion of a U6GlnUAG suppressor tRNA gene leads to an approximate 10-fold reduction 
of the functional titer (p-value <0.01) (Fig. 17). These results suggest that dsAAV2 vectors as 
designed can effectively carry GlnUAG suppressor tRNA genes without a drastic decrease in 
vector titer. Because of these encouraging results using dsAAV2 vectors, further studies were 
conducted using AAV vector system for expression of GlnUAG suppressor tRNAs. 
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Functional expression of U6GlnUAG suppressor tRNA using dsAAV2 vectors 
The ability of dsAAV2 viral vectors to express a suppressor tRNA at functionally 
relevant levels was examined by rescue of mutant GFP expression. Omission of the GFP 
reporter gene allowed for the insertion of three copies of the U6GlnUAG tRNA gene into a 
dsAAV2-ITR vector (Fig. 15F).dsAAV2 U6GlnUAG-3 vectors were used to transduce 
293/SEGFP cells that stably express a mutant GFP (SEGFP that has a premature termination 
codon)  (Koukuntla and Link 2009). FACS analysis (Fig. 18C) shows that full length GFP 
protein is expressed in 293/SEGFP cells transduced with dsAAV2-U6GlnUAG-3 vectors, 
indicating that suppressor tRNA is expressed to sufficient levels for the suppression of the 
premature stop codon in the SEGFP gene. It is encouraging that with an easily achievable 
vector titer, high level of GFP expression occurs suggesting activity of U6GlnUAG tRNA 
expressed through a dsAAV2 vector. These results suggest that dsAAV2 vectors may be 
suitable for functional in vitro expression of GlnUAG suppressor tRNAs. 
Preliminary in vivo studies using dsAAV2 vectors for delivery of GlnUAG suppressor 
tRNAs  
The utility of the dsAAV2 system was next tested in vivo for the transport and 
expression of suppressor tRNA genes. SEGFP mice that carry a mutant GFP gene with a 
premature termination codon at the third codon (Ro and Rannala 2004) were used as a model 
system to test the efficacy of dsAAV2-U6GlnUAG-3 vectors.  As described in Table 5, 
SEGFP mice were injected with dsAAV2-U6GlnUAG-3 vectors via the tail vein and liver 
tissues were harvested 12 weeks post-injection. The presence of dsAAV2 vectors in these 
tissues was verified by PCR amplification from extracted DNA (Fig. 19). RT-PCR for 
GlnUAG suppressor tRNA genes from extracted tissues was only positive in all the mice 
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injected with dsAAV2-U6GlnUAG3 vectors (Fig. 20). These results demonstrate that 
dsAAV2 viral vectors can effectively deliver GlnUAG suppressor tRNA genes in vivo.  
While RT-PCR shows that GlnUAG suppressor tRNA is transcribed in vivo (Fig. 20), 
these results do not indicate whether suppressor tRNA expression levels are sufficient for the 
suppression of the PCT in the GFP gene during translation. Suppression was assessed by 
Western analysis of total cell protein from liver tissues from these mice injected with 
dsAAV2-U6GlnUAG-3 vectors using an anti-GFP antibody for the detection of full-length 
GFP. Although GlnUAG suppressor tRNA was detected by RT-PCR in all the mice injected 
with dsAAV2-U6GlnUAG-3 vectors (Fig. 20), full length GFP protein was detected in only 
one mouse injected with undiluted 2x1011 genomes of dsAAV2-U6GlnUAG-3 vector (Fig. 
21). All other mice injected with dsAAV2-U6GlnUAG-3 vectors at other dilutions or under 
different conditions were completely negative for GFP protein expression. 
While long-term in vivo expression of suppressor tRNA might have deleterious 
effects, none of the mice administered with any of our test vectors expressing Glutamine 
Amber suppressor tRNA in this study showed any signs of trauma or discomfort even 3 
months post-injection. To test for any tissue pathology resulting from long term suppressor 
tRNA expression, 12 weeks after the vector injections, frozen liver sections were obtained 
from mice injected with dsAAV2-U6GlnUAG-3, dsAAV2EGFP or saline and were stained 
with hematoxylin and eosin for light microscopic examination. No detectable differences in 
tissue morphology were observed (Fig.22), indicating that long term in vivo expression of 
GlnUAG suppressor tRNA may not lead to any observable pathology. 
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Discussion           
It has been previously shown that glutamine amber suppressor tRNA can be stably 
expressed in 293 cells, and U6 promoter enhanced suppressor tRNAs have significantly 
higher suppression efficacies than suppressor tRNAs without an external U6 promoter 
(Koukuntla and Link 2009). Although U6 promoter enhanced NSTs have better suppression 
efficacies and can be stably expressed to suppress a PTC in 293 cells, there are no reports of 
any viral vectors used for in vivo delivery and expression of suppressor tRNAs. The data 
reported in this study suggest that dsAAV2 vectors are preferable for the expression of 
GlnUAG suppressor tRNAs genes. Importantly, these results show that dsAAV2 vectors may 
be used for the delivery and expression of GlnUAG suppressor tRNAs in vivo without 
obvious adverse side effects.  
For efficient suppression, enough suppressor tRNA expression is required for NSTs 
to compete with cognate tRNAs and translation termination factors (Drugeon, Jean-Jean et al. 
1997).  Our results with retroviral vectors demonstrating reduced titers while carrying 
GlnUAG tRNA was not entirely surprising, as previous studies have shown that RNA Pol III 
expression cassettes are not efficiently transcribed when located between retroviral LTRs 
(Ilves, Barske et al. 1996). Although alternative vector designs utilizing insulating sequences 
or artificial introns  may be useful to overcome the limitations noted in our initial results, we 
decided to do further in vivo studies using the AAV. Alternatively, use of other types of 
retroviral vectors, such as lentiviral based vectors for expressing suppressor tRNAs might be 
explored in future studies. 
A preliminary study was conducted to test the dsAAV2 vectors for their ability to 
carry and deliver suppressor tRNA genes in vitro and in vivo. Our results show that dsAAV2 
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vectors carrying U6GlnUAG suppressor tRNAs have approximately 10-fold lower titers than 
dsAAV2 vectors without suppressor tRNA genes. As titers in excess of 1015 AAV 
vectors/mL can now be produced (Buning, Perabo et al. 2008), a 10-fold reduction in AAV 
vector titer due to the presence of U6GlnUAG tRNA genes does not pose a serious problem 
for development of AAV vectors for delivery of suppressor tRNAs.  A premature stop codon 
in the SEGFP gene was successfully suppressed in vitro using GlnUAG suppressor tRNA 
genes carried in dsAAV2 vectors. For our initial in vivo studies, SEGFP mice were injected 
with various amounts of dsAAV2-U6GlnUAG-3 vectors for correction of a PTC in the 
SEGFP gene. But Western analysis suggests that GlnUAG suppressor tRNAs may be 
functional to suppress a PTC in the SEGFP gene in only one SEGFP mouse injected with 
undiluted 2x1011 genomes of dsAAV2-U6GlnUAG-3 vector. In future ongoing studies, it 
may be possible to increase suppression efficacy by either multiple injections of dsAAV2 
vectors carrying suppressor tRNA genes or by using alternate dsAAV vector serotypes. If 
multiple injections elicit an anti-vector response, it might be possible to deliver a higher dose 
of vector carrying suppressor tRNA genes the first time.  
For some diseases such as lysosomal storage diseases, very low levels of protein 
expression can restore normal phenotype or alleviate disease symptoms (Maire 2001; 
Kellermayer 2006). Therapeutically, low levels of suppression may be sufficient for the 
suppression of an actual nonsense mutation disease phenotype. In addition, if different 
serotypes of AAV vectors can be used to selectively target different tissues for transfer of 
suppressor tRNA genes. This could open a new avenue of treatment options for patients 
suffering with diseases caused due to nonsense mutations. Different serotypes of dsAAV 
vectors can be used to deliver and express different types of suppressor tRNAs in a tissue 
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specific manner for better suppression of nonsense mutations. dsAAV2 vectors are promising 
candidates for delivery of U6 GlnUAG suppressor tRNA genes in vivo. Availability of 
different AAV vector serotypes provides an opportunity to deliver various suppressor tRNAs 
in a tissue-specific manner. In several cases, the identity of the amino acid inserted at the 
PTC is not critical as long as translation is not prematurely terminated (Rio Frio, Wade et al. 
2008). In such scenarios, irrespective of the amino acid the suppressor tRNA is designed for, 
the most efficient suppressor tRNA could be used for PTC suppression. 
In conclusion, dsAAV2 vectors might be useful viral vectors for in vivo delivery of 
nonsense suppressor tRNAs. Preliminary in vivo results, especially the initial demonstration 
of the recovery of GFP expression in a single SEGFP mouse warrants further study. Efforts 
to retest these preliminary results are underway and use this budding technology on specific 
genetic disease model systems are warranted. 
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Figure 15: Design of viral vectors. 
 (A) pLEIN – Retroviral vector encoding GFP. (B) Retroviral vector with one copy of 
U6GlnUAG and one copy of GFP as a reporter gene. (C) pLEGFP-U6GlnUAG-Inv – One 
copy of U6GlnUAG was cloned into a retroviral vector in the inverse orientation along with 
one copy of GFP gene. (D) dsAAV2EGFP – dsAAV2 vector encoding a GFP gene. (E) 
dsAAV2-U6GlnUAG-EGFP –dsAAV2 vector encoding one copy of U6GlnUGA tRNA and 
one copy of GFP gene. (F) dsAAV2-U6GlnUAG-3 –Three copies of U6GlnUAG cloned into 
a dsAAV2 shuttle vector. 
  
Figure 16: MoMLV based retroviral vectors carrying U6GlnUAG have lower titers
293 cells were transduced with retroviral vectors 
U6GlnUAG suppressor tRNA
positive are represented in quadrant 4 (Q4). The GFP intensity in these cells can be measured 
in log scale on the horizontal axis. (A) U
pLEIN vector (C) 293 cells transduced with 
transduced with pLEGFP-U6GlnU
 
expressing normal GFP with and without 
 analyzed by FACS. The populations of cells that are GFP 
ntransduced 293 cells (B) 293 cells transduced with 
pLEGFP-U6GlnUAG vector (D) 293 cells 
AG-Inv retroviral vector. 
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Figure 17: Effect of U6GlnUAG 
293 cells were transduced with dsAAV2 vectors expressing normal GFP with and without 
U6GlnUAG suppressor tRNA
positive are represented in quadrant 4 (Q4). The GFP intensity in these cells can be measured 
in log scale on the horizontal axis. 
cells transduced with dsAAV2
dsAAV2EGFP vector. 
 
 
suppressor tRNA on dsAAV2 vector titer. 
 and analyzed by FACS. The populations of cells that are GFP 
(A) Untransduced 293 cells (negative control
-U6GlnUAG-EGFP vector. (C) Cells transduced with 
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Figure 18: U6GlnUAG can be functionally expressed through a dsAAV2 viral vector in 
293/SEGFP cells.  
FACS analysis of untransduced 293/SEGFP cells and 293/SEGFP cells transduced with
dsAAV2-U6GlnUAG-3 vector.
represented in quadrant 4 (Q4). The GFP intensity in these cells can be measured in log scale 
on the horizontal axis. (A) 293/SEGFP cells carry mutant GFP gene. Full length GFP i
expressed in these cells. (B) 293
(positive control) (C) 293/SEGFP
  
 The populations of cells that are GFP positive are 
/SEGFP cells transduced with dsAAV2-EGFP
 cells transduced with dsAAV2-U6GlnUAG
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Figure 19: PCR amplification of dsAAV2 vectors from SEGFP mouse tissues. 
Lanes 1 to7 represent RT PCR analysis of samples that correspond to mice shown in Table 1. 
Amplifications with primers specific for the GFP present in dsAAV2 vectors are shown in 
the upper panel. Amplifications with U6GlnUAG specific primers are shown in the lower 
panel. The sample in Lane 5 is from a negative control mouse injected with saline. Lane 8 
has positive control reactions using plasmid DNA as templates. 
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Figure 20: RT-PCR of U6GlnUAG from SEGFP mouse tissues.  
Lanes 1 to7 represent RT PCR analysis of samples that correspond to mice shown in Table 5. 
Amplification with U6GlnUAG-specific primers is shown in the upper panel. The middle 
panel shows reactions without reverse transcriptase, and the lower panel shows GAPDH 
mRNA product as loading control for the samples used for RT-PCR. 
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Figure 21: Western blot of SEGFP mouse tissue samples probed with anti- GFP 
antibodies 
SEGFP mice were injected with select amounts of either dsAAV2-U6GlnUAG-3 vectors 
(Lane 1 to 4) or dsAAV2-EGFP vectors (lane 6 and 7). Proteins from mouse injected with 
saline only (negative control) is in lane 5. Tissues in Lanes 1 to 7correspond to the mice 
shown in Table 5. One lane between 5 and 6 was left empty to avoid contamination between 
negative and positive samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GFP protein 
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Figure 22: Microscopic examination of tissues from mice expressing U6GlnUAG for 84 
days.  
Liver sections from mice injected with (A) saline, (B) dsAAV2-U6GlnUAG-3 vector or (C) 
dsAAV2-EGFP were fixed and stained with hematoxylin and eosin stains. The cryo-sections 
were examined for signs of pathology or trauma 84 days post-injection. 
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Mouse No. Virus injected Volume injected 
(µl) 
Vector Genomes 
Injected (x10-10) 
1 dsAAV2-U6GlnUAG-3 295 20 
2 dsAAV2-U6GlnUAG-3 1726 5 
3 dsAAV2-U6GlnUAG-3 1652 10 
4 dsAAV2-U6GlnUAG-3 1505 20 
5 Saline 1500 0 
6 dsAAV2-EGFP 295 20 
7 dsAAV2-EGFP 1700 5 
 
Table 5: Amount of dsAAV2 vectors injected into SEGFP mice.  
Mice 2, 3, 4, 5 and 7 were hydrodynamically injected with viral vectors diluted in saline. 
Mice 1 and 6 were injected with vectors without diluting in saline.  
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Chapter 4 
Summary 
In a growing human population and with advanced medical expertise, finding novel 
therapeutic options for genetic diseases that cannot be treated by current medical methods is 
becoming a rising priority. Gene therapy holds promise for treating inherited genetic diseases 
and is important enough to be termed the "fourth scientific revolution" after the medical 
developments that include surgery under anesthesia, the use of antibiotics and the use of 
vaccines (Huff, 1996). The objective of this study was to devise methods for using 
suppressor tRNAs in gene therapy of diseases caused by nonsense mutations. Although 
researchers (Temple, 1982) proposed suppressor tRNAs as gene therapy tools two decades 
ago, lately interest in this field has dwindled because of a combination of factors. The current 
study addressed some of the major concerns and made significant progress toward designing 
efficient viral vectors for using suppressor tRNAs in vivo. The study's major conclusions are 
summarized below. 
 
U6 promoter enhanced suppressor tRNAs have higher suppression efficacies. 
Most cellular tRNAs, including suppressor tRNAs, are differentially expressed 
(Srinivasan, 2001; Li, 1998). Suppressor tRNAs' differential expression patterns inhibit or 
decrease suppressor tRNA's expression in specific tissues, and thus limit the probability of 
using them for gene therapy in different cell types. Over the years, researchers have 
employed various methods to circumvent the problem of low suppressor tRNA expression. 
These methods include using multimers of suppressor tRNA genes (Buvoli, 2000) that 
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increases the amount of suppressor tRNA expressed in cells and using suppressor tRNAs 
derived from E. coli  along with the corresponding specific amino acyl synthetase in 
mammalian cells (K”hrer, 2004). Although such methods increase the suppression efficacy 
marginally (Drabkin, 1996), they do not specifically address the issue of suppressor tRNA's 
differential expression. 
A viable gene therapy protocol involving suppressor tRNAs requires novel method(s) 
that not only ensure NSTs' expression in different cell types, but also increased suppressor 
tRNA expression and suppression. The hypothesis was that an external promoter such as a 
human U6 promoter can be used to increase the transcription of a suppressor tRNA. 
Enhanced suppressor tRNA expression would increase the probability of cognate amino acyl 
synthetases efficiently charging the suppressor tRNAs with a corresponding amino acid. 
Eventually, higher amounts of charged suppressor tRNA in cells will lead to increased 
suppression efficacies. The U6 promoter was chosen because it is a constitutively active 
promoter that transcribes thousands of copies of small RNA genes (Huang, 2001). Lai et al 
had previously used a U6 promoter to drive the expression of a normal tyrosine gene (Lai, 
2004). To test the hypothesis, a GlnUAG suppressor tRNA was cloned downstream of a 
human U6 promoter. A GFP gene with an amber stop codon mutation was used as a reporter 
gene to measure the GlnUAG suppressor tRNA efficacy. In absence of GlnUAG suppressor 
tRNA, the mutant GFP mRNA is not translated and GFP protein is not expressed. But in the 
presence of an active GlnUAG suppressor tRNA, GFP mRNA with a premature amber stop 
codon is translated into a full -length GFP protein. Suppressor tRNA activity could be 
measured by quantifying the GFP expression.  
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The data show that the human U6 promoter enhanced GlnUAG suppressor tRNA has 
significantly higher suppression efficacy than a GlnUAG suppressor tRNA without a U6 
promoter. The suppression achieved using a single copy of the U6 promoter-enhanced 
suppressor tRNA was significantly higher than the suppression of PTCs observed using eight 
copies of GlnUAG suppressor tRNAs without a U6 promoter. The study's other major 
finding was that a U6GlnUAG suppressor tRNA can be expressed in a higher percentage of 
cells than GlnUAG tRNA (without a U6 promoter). This observation is important because it 
shows that the presence of a U6 promoter upstream of a GlnUAG suppressor tRNA increases 
the probability of the suppressor tRNA function in vitro.  
 
U6 promoter enhanced GlnUAG suppressor tRNA can be stably expressed in 293 cells. 
A crucial aspect of gene therapy using suppressor tRNAs is to ensure sustained long 
term expression of NSTs in cells. Previous reports have suggested that stable suppressor 
tRNA expressions can be fatal to cells (Hudziak, 1982). Stable expression of Amber serine 
suppressor tRNA in Drosophila melanogaster resulted in sterility (Laski, 1989). It was 
speculated that stable in vitro suppressor tRNA expression leads to read through of normal 
stop codons resulting in abnormally long proteins that might cause various deleterious effects 
(Bienz, 1981). However, tobacco plants constitutively expressing suppressor tRNA are 
normal (Choisne, Martin-Canadell et al. 1997) and in other studies suppressor tRNA 
mediated toxicity was not observed (Temple, Dozy et al. 1982; Panchal, Wang et al. 1999). 
But use of suppressor tRNAs for gene therapy may require that NSTs are stably expressed in 
mammalian cells.  
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This study's second hypothesis was that a U6 promoter enhanced GlnUAG suppressor 
tRNA could be stably expressed in mammalian cells to suppress a premature stop codon. To 
test this hypothesis, A549 and 293 cells were first transduced with lentiviral vectors 
expressing a mutant GFP gene. The mutant GFP had an amber premature stop codon that 
prevented these cells from expressing any GFP protein. But when these cells were transfected 
a with U6GlnUAG suppressor tRNA, they expressed full length GFP protein. All the GFP 
positive cells were sorted by FACS and placed in culture. The presence of U6GlnUAG tRNA 
in these GFP positive cells was confirmed by PCR. Even after several rounds of cell culture, 
these cells remained GFP positive indicating steady and stable GlnUAG suppressor tRNA 
expression. Thus, the results show that GlnUAG suppressor tRNA was stably expressed in 
293 and A549 cells. 
Stable expression of suppressor tRNAs in mammalian cells may cause proteomic 
changes. To detect such changes, whole cell proteins from 293 cells with and without stable 
GlnUAG suppressor tRNA expression were compared by 2D gel electrophoresis. Whole cell 
proteins were run on two different 2D polyacrylamide gels and stained with silver stain. The 
resulting protein spots were compared by Progenesis software. The data showed five unique  
protein spots on the gel carrying proteins from 293 cells with no suppressor tRNA; and there 
were 13 unique protein spots on the gel carrying proteins from 293 cells that stably express 
U6 promoter enhanced GlnUAG suppressor tRNA. When protein expression levels were 
compared, 293 cells expressing GlnUAG tRNA had 4% of total proteins that had higher 
expression compared to 293 cells without any suppressor tRNA expression. To put these 
results in perspective, when Xenopus ooctyes were injected with normal tRNATrp, about 3%  
of the proteins showed differences  (Bienz, Kubli et al. 1981).  If readthrough occurred 
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universally at the UAG stop codon, a much larger difference would be expected since 26% of 
all human transcripts have UAG as regular stop codons. Our data therefore suggest that the 
proteomic changes seen in 293 cells stably expressing GlnUAG tRNAs may to be modestly 
significant. A similar experiment performed to study read through effects of different 
suppressor tRNAs (Bienz, Kubli et al. 1981) suggested that there is no significant read 
through of cellular proteins in the presence of suppressor tRNAs. 
Thus, the data here show that U6 promoter enhanced GlnUAG suppressor tRNA can 
be stably expressed in mammalian cells and this stable expression may not cause significant 
read through of normal cellular stop codons.  
 
Presence of U6 promoter enhanced GlnUAG suppressor tRNA affects MoMLV 
retroviral vector titer but does not significantly affect Adeno-associated viral vector 
titer. 
An ideal viral vector system for expressing suppressor tRNAs should be able to carry 
and express suppressor tRNAs  at functionally relevant levels, transduce different kinds of 
cell types, cause minimal or no damage to the cells, provide for stable and long term 
expression of suppressor tRNAs, and, elicit little or no immune response. Although there are 
no reports of retroviral vectors or AAV vectors that can express suppressor tRNAs, both 
retroviral and AAV vectors (Lech, 2008; Tai, 2008; Buning, 2008; Daya, 2008) meet most of 
the aforementioned criteria required for a viral vector system to express suppressor tRNAs.  
In our preliminary studies, one of the objectives was to study the effects of U6 
promoter enhanced GlnUAG suppressor tRNAs on either specific MoMLV retroviral vector 
constructs or dsAA2 vectors. The constructs were designed such that any change in vector 
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titer could be quantified by measuring the reporter gene expression. Significant decreases in 
vector titers in presence of U6GlnUAG tRNA may indicate that the suppressor tRNA might 
interfere with viral vector replication or production, or might inhibit its ability to transduce 
cells and transfer genes.  
U6GlnUAG tRNA and a normal GFP gene were cloned into retroviral and dsAAV2 
vectors. 293 cells were transduced with these viral vectors and the GFP expression was 
quantified by FACS analysis. The results from the above experiment showed that the titers of 
retroviral vectors carrying U6GlnUAG suppressor tRNA were significantly lower than the 
titer of retroviral vectors without any suppressor tRNA. Therefore, the data demonstrate for 
the specific retroviral constructs tested that the presence of the U6GlnUAG tRNA strongly 
interferes with vector titer.  
Next, dsAAV2 vectors were tested for their ability to carry suppressor tRNAs. When 
dsAAV2 vectors with and without U6 promoter enhanced GlnUAG suppressor tRNA were 
compared, the titer of dsAAV2 decreased by approximately tenfold in the presence of a 
U6GlnUAG suppressor tRNA. These results suggest that dsAAV2 vectors as designed can 
effectively carry GlnUAG suppressor tRNA genes without a drastic decrease in vector titer. 
Because of these encouraging results using dsAAV2 vectors, further studies were conducted 
using AAV vector system for expression of GlnUAG suppressor tRNAs. 
 
Functional expression of U6GlnUAG suppressor tRNA using dsAAV2 vectors 
After confirming the ability of dsAAV2 vectors to carry U6GlnUAG tRNA, the 
ability of dsAAV2 viral vectors to express a suppressor tRNA at functionally relevant levels 
was examined by rescue of mutant GFP expression. dsAAV2 U6GlnUAG-3 vectors were 
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used to transduce 293/SEGFP cells that stably express a mutant GFP (SEGFP that has a 
premature termination codon. FACS analysis showed that full length GFP protein is 
expressed in 293/SEGFP cells transduced with dsAAV2-U6GlnUAG-3 vectors, indicating 
that suppressor tRNA is expressed to sufficient levels for the suppression of the premature 
stop codon in the SEGFP gene. It is encouraging that with an easily achievable vector titer 
high level of GFP expression occurs suggesting activity of U6GlnUAG tRNA expressed 
through a dsAAV2 vector. These results suggest that dsAAV2 vectors may be suitable for 
functional in vitro expression of GlnUAG suppressor tRNAs. 
 
Preliminary in vivo studies using dsAAV2 vectors for delivery of GlnUAG suppressor 
tRNAs  
The utility of the dsAAV2 system was next tested in vivo for the delivery and 
expression of suppressor tRNA genes. SEGFP mice that carry a mutant GFP gene with a 
premature termination codon at the third codon were used as a model system to test the 
efficacy of dsAAV2-U6GlnUAG-3 vectors. A dsAAV2 vector expressing a normal GFP 
gene was used as a positive control and was injected into SEGFP mice. Mice injected with 
saline were used as negative controls. SEGFP mice were injected with different vector doses 
of dsAAV2-U6GlnUAG-3 vectors via the tail vein and liver tissues were harvested 12 weeks 
post-injection. The presence of dsAAV2 vectors in these tissues was verified by PCR 
amplification from extracted DNA. RT-PCR for GlnUAG suppressor tRNA genes from 
extracted tissues was only positive in all the mice injected with dsAAV2-U6GlnUAG3 
vectors. These results suggest that dsAAV2 viral vectors may be effective in deliver of 
GlnUAG suppressor tRNA genes in vivo. It should be noted that of all the SEGFP mice 
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injected with different amounts of dsAAV2-U6GlnUAG-3 vectors, GFP expression was 
observed in only one mouse. 
Next, proteins from liver tissues of SEGFP mice injected with various dsAAV2 
vectors were run on an SDS-PAGE gel, and an anti-GFP antibody was used to detect GFP 
protein by Western analysis. The results showed that full length GFP protein was expressed 
only in one mouse injected with undiluted 2 x 1011 dsAAV2-U6GlnUAG vector genomes. 
Hence our preliminary data from one SEGFP mouse suggests an optimal dose of dsAAV2 
vectors that may be used to express GlnUAG suppressor tRNA in vivo to suppress a 
nonsense mutation for ongoing studies. While long-term in vivo expression of suppressor 
tRNA might have deleterious effects, none of the mice expressing Glutamine Amber 
suppressor tRNA in this study showed any sign of trauma or discomfort even 3 months post-
injection.  
 
Final thoughts and future directions 
In future studies, it may be possible to increase suppression efficacy by either 
multiple injections of dsAAV2 vectors carrying suppressor tRNA genes or by using alternate 
dsAAV vector serotypes. If multiple injections elicit an anti-vector response, it might be 
possible to deliver a higher dose of vector carrying suppressor tRNA genes the first time. Our 
results suggest that dsAAV vectors could potentially be utilized for in vivo suppressor tRNA 
gene delivery and expression.  
Based upon our initial in vivo finding in one SEGFP mouse, dsAAV2 vectors may be 
promising candidates for delivery of U6 GlnUAG suppressor tRNA genes in vivo. 
Availability of different AAV vector serotypes provides an opportunity to deliver various 
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suppressor tRNAs in a tissue-specific manner. In several cases, the identity of the amino acid 
inserted at the PTC is not critical as long as translation is not prematurely terminated (Rio 
Frio, Wade et al. 2008). In such scenarios, irrespective of the amino acid the suppressor 
tRNA is designed for, the most efficient suppressor tRNA could be used for PTC 
suppression. 
In conclusion, the data here demonstrate that U6 enhanced suppressor tRNAs have 
higher suppression efficacy, can be stably expressed in mammalian cells and stable 
expression of suppressor tRNAs may not lead to significant read through of normal cellular 
proteins. We also demonstrate in a single SEGFP mouse that when expressed through a 
dsAAV2 vector, a GlnUAG suppressor tRNA may suppress an amber nonsense mutation in 
vivo. Preliminary in vivo results, especially the initial demonstration of the recovery of GFP 
expression in a SEGFP mouse warrants further study. Efforts to expand these preliminary 
results are ongoing, as are plans to use this budding technology on specific genetic disease 
model systems. This study's findings open exciting new possibilities for the use of suppressor 
tRNAs in gene therapy of nonsense mutation associated diseases.  
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